Directory of Researchers

AOI Takashi
Graduate School of Science, Technology and Innovation / Department of Science, Technology and Innovation
Professor
Medicine
Last Updated :2021/09/13

Researcher Profile and Settings

Affiliation

  • <Faculty / Graduate School / Others>

    Graduate School of Science, Technology and Innovation / Department of Science, Technology and Innovation
  • <Related Faculty / Graduate School / Others>

    School of Medicine / Faculty of Medicine, Graduate School of Medicine / Faculty of Medical Sciences

Teaching

  • School of Medicine / Faculty of Medicine, 2020, Embryology
  • Graduate School of Medicine, 2020, Cellular and Molecular Medicine
  • Graduate School of Science, Technology and Innovation, 2020, Introduction to Advanced Medicine
  • Graduate School of Science, Technology and Innovation, 2020, Advanced Project Research
  • Graduate School of Science, Technology and Innovation, 2020, Presentation Exercises
  • Graduate School of Science, Technology and Innovation, 2020, Master's Thesis
  • Graduate School of Science, Technology and Innovation, 2020, Advanced Science and Technology Research
  • Graduate School of Science, Technology and Innovation, 2020, Research on Science, Technology and Innovation 1
  • Graduate School of Science, Technology and Innovation, 2020, Research on Science,Technology and Innovation 2
  • Graduate School of Science, Technology and Innovation, 2020, Advanced Course on the Regenerative Medicine
  • Graduate School of Science, Technology and Innovation, 2020, Project-Based Learning of Entrepreneurship in Science and Technology
  • Graduate School of Science, Technology and Innovation, 2020, Science,Technology and Innovation Strategy Project Research

Research Activities

Research Areas

  • Life sciences / Cell biology

Committee Memberships

  • Jul. 2021 - Present, AMED, 「創薬支援推進事業 創薬シーズ実用化支援基盤整備事業」課題評価委員
  • Apr. 2021 - Present, 一般社団法人 日本再生医療学会, 再生医療誌編集委員会委員
  • Apr. 2021 - Present, 一般社団法人 日本再生医療学会, 行政等対応委員会委員
  • Apr. 2021 - Present, 一般社団法人 日本再生医療学会, 総務委員会副委員長
  • Apr. 2021 - Present, 一般社団法人 日本再生医療学会, Regenerative Therapy運営委員会委員
  • Apr. 2021 - Present, 一般社団法人 日本再生医療学会, 理事
  • Feb. 2021 - Present, 株式会社バイオパレット, 「ヒト組織利用研究倫理審査委員会 」委員
  • Dec. 2020 - Present, AMED, 「再生実用化基盤整備促進事業」課題評価委員
  • Apr. 2020 - Present, AMED, 「新興・再興感染症に対する革新的医薬品等開発推進研究事業」課題評価委員
  • Apr. 2020 - Present, AMED, 「再生医療実現拠点ネットワークプログラム iPS細胞研究中核拠点、疾患・組織別実現化研究拠点」プログラムオフィサー
  • Feb. 2020 - Present, 独立行政法人医薬品医療機器総合機構, 科学委員会委員
  • Jan. 2020 - Present, AMED, 「再生医療実現拠点ネットワークプログラム 幹細胞・再生医学イノベーション創出プログラム」課題評価委員
  • Dec. 2019 - Present, 独立行政法人日本学術振興会, 科学研究費委員会専門委員
  • Aug. 2019 - Present, AMED, 「再生医療実現拠点ネットワークプログラム 再生医療の実現化支援課題」課題評価委員
  • Aug. 2019 - Present, 一般社団法人バイオロジクス研究・トレーニングセンター, 理事
  • Jun. 2019 - Present, 国立医薬品食品衛生研究所, 医療研究開発推進事業費補助金「再生医療等臨床研究を支援する再生医療ナショナルコンソーシアムの実現」分担研究協力者
  • Jan. 2018 - Present, 一般財団法人日本消化器病学会, 再生医療推進委員会委員
  • Aug. 2017 - Present, AMED, 「医療研究開発革新基盤創出事業(CiCLE)」課題評価委員
  • Apr. 2017 - Present, AMED, 「再生医療臨床研究促進基盤整備事業」課題評価委員
  • Oct. 2016 - Present, 一般財団法人公正研究推進協会, 委員会委員
  • Apr. 2016 - Present, 大阪大学, 第一特定認定再生医療等委員会委員
  • Aug. 2015 - Present, AMED, 「産学連携医療イノベーション創出プログラム委員会」委員
  • Apr. 2015 - Present, 京都府立医科大学, 特定認定再生医療等委員会委員
  • Jun. 2020 - Mar. 2021, AMED, 「再生医療実現拠点ネットワークプログラム 幹細胞・再生医学イノベーション創出プログラム(国際共同研究)」課題評価委員
  • Apr. 2020 - Mar. 2021, AMED, 「再生医療実現拠点ネットワークプログラム(疾患・組織別実用化研究拠点(拠点C))」課題評価委員
  • Mar. 2020 - Mar. 2021, 一般社団法人バイオロジクス研究・トレーニングセンター, 利益相反委員会 委員
  • Nov. 2019 - Mar. 2021, 国立研究開発法人理化学研究所, リソース検討委員
  • May 2019 - Mar. 2021, 株式会社メディカルレビュー社, 日本再生医療学会雑誌『再生医療』編集委員会委員
  • Jun. 2017 - Mar. 2021, 日本再生医療学会, 理事長補佐
  • Apr. 2015 - Mar. 2021, AMED, 「再生医療実現拠点ネットワークプログラム 再生医療の実現化ハイウェイ」プログラム オフィサー
  • Feb. 2020 - Jul. 2020, 藤田医科大学, 特定認定再生医療等委員会委員
  • Jul. 2019 - Mar. 2020, 日本赤十字社 血液事業本部, 懇談会 委員
  • Jan. 2019 - Mar. 2020, 国立研究開発法人 国立循環器病研究センター, 治験審査委員会 招聘委員
  • Jul. 2018 - Mar. 2019, AMED, 「再生医療実現拠点ネットワークプログラム(技術開発個別課題)事業」課題評価委員
  • Apr. 2017 - Mar. 2019, AMED, 「疾患特異的iPS細胞の利活用促進・難病研究加速プログラム課題評価委員会」委員
  • Jun. 2016 - Mar. 2018, 国立医薬品食品衛生研究所, 「培養細胞を用いた基礎研究ならびに創薬研究開発のための細胞培養ガイダンス案」WG委員
  • Apr. 2016 - Mar. 2018, 厚生労働省, 「医薬品・医療機器薬事戦略懇談会」構成員
  • Nov. 2015 - Mar. 2018, 国立研究開発法人科学技術振興機構, 「斉藤全能性エピゲノムプロジェクト」事後評価(最終評価)委員
  • Apr. 2014 - Mar. 2018, 独立行政法人医薬品医療機器総合機構, 専門委員
  • Sep. 2017 - Jan. 2018, 京都大学iPS細胞研究所, 「研究公正調査委員会」委員
  • Feb. 2016 - Jan. 2018, 大阪大学大学院, 薬学研究科テニュアトラック運営委員会学外委員
  • Oct. 2016 - Mar. 2017, 国立研究開発法人 医薬基盤・健康・栄養研究所, 「経血管的投与肝再生医療等製品に関する評価指標」WG委員
  • Jun. 2016 - Mar. 2017, 国立研究開発法人 医薬基盤・健康・栄養研究所, 「径冠動脈的投与再生医療等製品に関する評価指標(非臨床)」WG委員
  • Dec. 2015 - Mar. 2017, AMED, 「医療情報の高度利用による医療システムの研究開発」中間評価委員
  • Nov. 2014 - Mar. 2017, 国立医薬品食品衛生研究所, 「再生医療等製品の原材料としてのヒト多能性幹細胞の品質についての考え方」WG委員
  • Dec. 2013 - Oct. 2016, 大阪大学医学部附属病院, ヒト幹細胞臨床研究審査委員会及び未来医療臨床研究審査・評価委員会委員
  • Jun. 2016 - Sep. 2016, 京都大学再生医科学研究所, 任期制教員の再任審査に関する外部評価委員会委員
  • Dec. 2015 - Mar. 2016, 文部科学省研究振興局, 「再生医療実現拠点ネットワークプログラム」中間評価委員会委員
  • Sep. 2015 - Mar. 2016, 国立医薬品食品衛生研究所, 「再生医療等製品(ヒト細胞加工製品)造腫瘍性評価ガイドライン案策定」合同WG委員
  • Sep. 2015 - Mar. 2016, AMED, 再生医療実現拠点ネットワークプログラム 研究開発課題評価委員会委員
  • Aug. 2015 - Mar. 2016, 国立研究開発法人 医薬基盤・健康・栄養研究所, 「重症心不全細胞治療用細胞懸濁系冠動脈的投与再生医療等製品に関する評価指標」WG委員
  • Jun. 2014 - Mar. 2016, 独立行政法人医薬品医療機器総合機構, 科学委員会専門部会委員
  • Mar. 2013 - Mar. 2015, 独立行政法人科学技術振興機構, 再生医療実現拠点ネットワーク事業 再生医療の実現化ハイウェイプログラムオフィサー
  • Apr. 2013 - Sep. 2014, 日本医学会総会 展示委員
  • Jun. 2014 - Aug. 2014, 独立行政法人新エネルギー・産業技術総合開発機構(NEDO), ワーキング委員
  • Oct. 2013 - Mar. 2014, 厚生労働省, 「再生医療等の安全性確保等のための基準策定に関する研究」WG委員

Published Papers

  • Microenvironment pH-Induced Selective Cell Death for Potential Cancer Therapy Using Nanofibrous Self-Assembly of a Peptide Amphiphile

    Shota Yamamoto, Kanon Nishimura, Kenta Morita, Sayuki Kanemitsu, Yuki Nishida, Tomoyuki Morimoto, Takashi Aoi, Atsuo Tamura, Tatsuo Maruyama

    May 2021, English

  • Yasufumi Koterazawa, Michiyo Koyanagi-Aoi, Keiichiro Uehara, Yoshihiro Kakeji, Takashi Aoi

    BACKGROUND: The esophagus is known to be derived from the foregut. However, the mechanisms regulating this process remain unclear. In particular, the details of the human esophagus itself have been poorly researched. In this decade, studies using human induced pluripotent stem cells (hiPSCs) have proven powerful tools for clarifying the developmental biology of various human organs. Several studies using hiPSCs have demonstrated that retinoic acid (RA) signaling promotes the differentiation of foregut into tissues such as lung and pancreas. However, the effect of RA signaling on the differentiation of foregut into esophagus remains unclear. METHODS: We established a novel stepwise protocol with transwell culture and an air-liquid interface system for esophageal epithelial cell (EEC) differentiation from hiPSCs. We then evaluated the effect of all-trans retinoic acid (ATRA), which is a retinoic acid receptor (RAR)α, RARβ and RARγ agonist, on the differentiation from the hiPSC-derived foregut. Finally, to identify which RAR subtype was involved in the differentiation, we used synthetic agonists and antagonists of RARα and RARγ, which are known to be expressed in esophagus. RESULTS: We successfully generated stratified layers of cells expressing EEC marker genes that were positive for lugol staining. The enhancing effect of ATRA on EEC differentiation was clearly demonstrated with quantitative reverse transcription polymerase chain reaction, immunohistology, lugol-staining and RNA sequencing analyses. RARγ agonist and antagonist enhanced and suppressed EEC differentiation, respectively. RARα agonist had no effect on the differentiation. CONCLUSION: We revealed that RARγ activation promotes the differentiation of hiPSCs-derived foregut into EECs.

    16 Jun. 2020, Journal of gastroenterology, English, Domestic magazine

    [Refereed]

    Scientific journal

  • Witta Kartika Restu, Shota Yamamoto, Yuki Nishida, Hirotoshi Ienaga, Takashi Aoi, Tatsuo Maruyama

    The present study reports that a short oligopeptide D-P1, consisting of only five D-amino acids, self-assembled into entangled nanofibers to form a hydrogel that functioned as a scaffold for cell cultures. D-P1 (Ac-D-Phe-D-Phe-D-Phe-Gly-D-Lys) gelated aqueous buffer solution and water at a minimum gelation concentration of 0.5 wt%. The circular dichroism (CD) measurements demonstrated the formation of a β-sheet structure in the self-assembly of D-P1. We investigated the gelation properties and CD spectra of both the D- and L-forms of the oligopeptide, and found only a minimal difference between them. The D-P1 hydrogel was resistant to a protease, whereas the L-P1 hydrogel was rapidly degraded. Both oligopeptides exhibited nontoxic properties to human cancer cells and embryoid bodies (EBs) derived from human-induced pluripotent stem cells. Additionally, we succeeded in forming spheroids of HeLa cells on the D-P1 hydrogel, which indicates the potential of this hydrogel for 3-dimensional cell culture.

    Jun. 2020, Materials science & engineering. C, Materials for biological applications, 111, 110746 - 110746, English, International magazine

    [Refereed]

  • Ryusaku Matsumoto, Hidetaka Suga, Takashi Aoi, Hironori Bando, Hidenori Fukuoka, Genzo Iguchi, Satoshi Narumi, Tomonobu Hasegawa, Keiko Muguruma, Wataru Ogawa, Yutaka Takahashi

    Pituitary develops from oral ectoderm in contact with adjacent ventral hypothalamus. Impairment in this process results in congenital pituitary hypoplasia (CPH); however, there have been no human disease models for CPH thus far, prohibiting the elucidation of the underlying mechanisms. In this study, we established a disease model of CPH using patient-derived induced pluripotent stem cells (iPSCs) and 3D organoid technique, in which oral ectoderm and hypothalamus develop simultaneously. Interestingly, patient iPSCs with a heterozygous mutation in the orthodenticle homeobox 2 (OTX2) gene showed increased apoptosis in the pituitary progenitor cells, and the differentiation into pituitary hormone-producing cells was severely impaired. As an underlying mechanism, OTX2 in hypothalamus, not in oral ectoderm, was essential for progenitor cell maintenance by regulating LHX3 expression in oral ectoderm via FGF10 expression in the hypothalamus. Convincingly, the phenotype was reversed by the correction of the mutation, and the haploinsufficiency of OTX2 in control iPSCs revealed a similar phenotype, demonstrating that this mutation was responsible. Thus, we established an iPSC-based congenital pituitary disease model, which recapitulated interaction between hypothalamus and oral ectoderm and demonstrated the essential role of hypothalamic OTX2.

    03 Feb. 2020, The Journal of clinical investigation, 130 (2), 641 - 654, English, International magazine

    [Refereed]

  • Chieko Hosaka, Makoto Kunisada, Michiyo Koyanagi-Aoi, Taro Masaki, Chihiro Takemori, Mariko Taniguchi-Ikeda, Takashi Aoi, Chikako Nishigori

    Induced pluripotent stem cell (iPSC) technology offers a novel approach for conversion of human primary fibroblasts into melanocytes. During attempts to explore various protocols for differentiation of iPSCs into melanocytes, we found a distinct and self-renewing cell lineage that could differentiate into melanocytes, named as melanocyte precursor cells (MPCs). The MPCs exhibited a morphology distinctive from that of melanocytes, in lacking either the melanosomal structure or the melanocyte-specific marker genes MITF, TYR, and SOX10. In addition, gene expression studies in the MPCs showed high-level expression of WNT5A, ROR2, which are non-canonical WNT pathway markers, and its related receptor TGFβR2. In contrast, MPC differentiation into melanocytes was achieved by activating the canonical WNT pathway using the GSK3β inhibitor. Our data demonstrated the distinct characteristic of MPCs' ability to differentiate into melanocytes, and the underlying mechanism of interfacing between canonical WNT signaling pathway and non-canonical WNT signaling pathway.

    Sep. 2019, Pigment cell & melanoma research, 32 (5), 623 - 633, English, International magazine

    [Refereed]

    Scientific journal

  • 「多能性幹細胞培養の留意点」の提案

    青井 貴之, 浅香 勲, 阿久津 英憲, 伊藤 弓弦, 片岡 健, 諫田 泰成, 小島 肇, 関野 祐子, 末盛 博文, 中川 誠人, 中村 和昭, 中村 幸夫, 藤井 万紀子, 古江-楠田 美保, 山崎 大樹, Good Cell Culture, Practice検討のためのワーキンググループ

    近年、ヒト胚性幹(ES)細胞やヒト人工多能性幹(iPS)細胞等のヒト多能性幹細胞は、基礎研究のみならず、創薬研究、再生医療への応用など、広い分野でその利用が期待されている。それに伴い、培養資材の供給など研究環境が整備され、ヒト多能性幹細胞の培養が容易に実施可能な状況となり、利用者が増加している。一方で研究者・作業者間において、技術とその背景となる基本概念の共有と、研究結果の再現性の担保が課題である。ヒト多能性幹細胞は従来利用されてきた体性細胞とは異なる点が多く、培養経験者であっても留意すべき点が多い。そこで、ヒト多能性幹細胞が有効に活用されることを期待し、「多能性幹細胞培養の留意点」案を作成した。本留意点案は、ヒト多能性幹細胞の使用開始にあたり確認すべき内容を、7項目(法令・指針と同意・MTA、多能性幹細胞の多様性、培養資材、解凍作業、培地交換と継代作業、凍結操作、培養管理)にまとめた。この留意点の概念が多能性幹細胞の細胞培養を行う研究者・作業者により共有され、日本の細胞培養技術が上進し、多能性幹細胞を用いた研究の利用と信頼性が向上することを期待する。(著者抄録)

    日本組織培養学会, Aug. 2019, 組織培養研究, 38 (3), 135 - 143, Japanese

  • Kotaro Suzuki, Michiyo Koyanagi-Aoi, Keiichiro Uehara, Nobuyuki Hinata, Masato Fujisawa, Takashi Aoi

    For augmentation or reconstruction of urinary bladder after cystectomy, bladder urothelium derived from human induced pluripotent stem cells (hiPSCs) has recently received focus. However, previous studies have only shown the emergence of cells expressing some urothelial markers among derivatives of hiPSCs, and no report has demonstrated the stratified structure, which is a particularly important attribute of the barrier function of mature bladder urothelium. In present study, we developed a method for the directed differentiation of hiPSCs into mature stratified bladder urothelium. The caudal hindgut, from which the bladder urothelium develops, was predominantly induced via the high-dose administration of CHIR99021 during definitive endoderm induction, and this treatment subsequently increased the expressions of uroplakins. Terminal differentiation, characterized by the increased expression of uroplakins, CK13, and CK20, was induced with the combination of Troglitazone + PD153035. FGF10 enhanced the expression of uroplakins and the stratification of the epithelium, and the transwell culture system further enhanced such stratification. Furthermore, the barrier function of our urothelium was demonstrated by a permeability assay using FITC-dextran. According to an immunohistological analysis, the stratified uroplakin II-positive epithelium was observed in the transwells. This method might be useful in the field of regenerative medicine of the bladder.

    19 Jul. 2019, Scientific reports, 9 (1), 10506 - 10506, English, International magazine

    [Refereed]

    Scientific journal

  • iPS作製技術を用いた人工骨肉腫幹細胞株の樹立

    藤原周一, Kawamoto Teruya, 青井貴之, 小寺澤康文, Hara Hitomi, 深瀬直政, 蒲田悦子, 竹森俊幸, 秋末敏宏, 黒田良祐

    (公社)日本整形外科学会, Aug. 2018, 日本整形外科学会雑誌, 92 (8), S1812 - S1812, Japanese

  • Proposal for “Fundamental principles for microscopic observation of cultured cells”

    AOI TAKASHI

    2018, Tiss. Cult. Res. Commun, 37, 123, Japanese

    [Refereed]

    Scientific journal

  • Daisuke Watanabe, Michiyo Koyanagi-Aoi, Mariko Taniguchi-Ikeda, Yukiko Yoshida, Takeshi Azuma, Takashi Aoi

    γδT cells constitute a small proportion of lymphocytes in peripheral blood. Unlike αβT cells, the anti-tumor activities are exerted through several different pathways in a MHC-unrestricted manner. Thus, immunotherapy using γδT cells is considered to be effective for various types of cancer. Occasionally, however, ex vivo expanded cells are not as effective as expected due to cell exhaustion. To overcome the issue of T-cell exhaustion, researchers have generated induced pluripotent stem cells (iPSCs) that harbor the same T-cell receptor (TCR) genes as their original T-cells, which provide nearly limitless sources for antigen-specific cytotoxic T lymphocytes (CTLs). However, these technologies have focused on αβT cells and require a population of antigen-specific CTLs, which are purified by cell sorting with HLA-peptide multimer, as the origin of iPS cells. In the present study, we aimed to develop an efficient and convenient system for generating iPSCs that harbor rearrangements of the TCRG and TCRD gene regions (γδT-iPSCs) without cell-sorting. We stimulated human whole peripheral blood mononuclear cell (PBMC) culture using Interleukin-2 and Zoledronate to activate γδT cells. Gene transfer into those cells with the Sendai virus vector resulted in γδT cell-dominant expression of exogenous genes. The introduction of reprogramming factors into the stimulated PBMC culture allowed us to establish iPSC lines. Around 70% of the established lines carried rearrangements at the TCRG and TCRD gene locus. The γδT-iPSCs could differentiate into hematopoietic progenitors. Our technology will pave the way for new avenues toward novel immunotherapy that can be applied for various types of cancer. Stem Cells Translational Medicine 2018 7:34–44.

    John Wiley and Sons Ltd., 01 Jan. 2018, Stem Cells Translational Medicine, 7 (1), 34 - 44, English

    [Refereed]

    Scientific journal

  • Ryo Ishida, Michiyo Koyanagi-Aoi, Nobu Oshima, Yoshihiro Kakeji, Takashi Aoi

    Cancer stem cells (CSC) are capable of reconstructing cancer tissues, are involved in both recurrence and metastasis, and contribute to therapeutic resistance. Therefore, elucidating the molecular mechanism in CSCs is important to successfully treat unresectable cancers. Previously, we observed that colon cancer stem-like cells can be induced from human colon cancer cell lines by retrovirally introducing OCT3/4, SOX2, and KLF4, and we have designated such cells as induced cancer stem cells (iCSC). In the current study, we used iCSCs to evaluate the molecular mechanism of colon CSCs and developed new methods to control them. The spheres that were derived in vitro from the iCSCs, but not those from parental cells, mimicked human colon cancer tissues in terms of their immunohistologic patterns; therefore, sphere-forming ability was assessed as a measure of the tissuere-constructing ability of iCSCs. Interestingly, the calcineurin inhibitor FK506 enhanced the sphere-forming ability of iCSCs, whereas GSK3 inhibition by RNAi, CHIR99021, and valproic acid (VPA) impeded the sphere-forming ability and expansion of iCSCs. FK506 and GSK3 inhibition showed the opposite effect regarding the NFATc3 localization of iCSCs. These data reveal the crucial role that NFAT localization, as regulated by calcineurin and GSK3, plays in the tissue-reconstructing ability of colon cancer stem cells and the potential of GSK3 inhibitors, such as VPA, in colon cancer stem cell-targeting therapy. (C) 2017 AACR.

    AMER ASSOC CANCER RESEARCH, Oct. 2017, MOLECULAR CANCER RESEARCH, 15 (10), 1455 - 1466, English

    [Refereed]

    Scientific journal

  • 人工肺癌幹細胞を用いた、肺癌組織再構築と新規治療法開発の試み

    OGAWA HIROYUKI, AOI MICHIYO, AOI TAKASHI, MANIWA YOSHIMASA

    Sep. 2017, 肺癌, 57 (5), 416, Japanese

    Research society

  • Hiroyuki Ogawa, Michiyo Koyanagi-Aoi, Kyoko Otani, Yoh Zen, Yoshimasa Maniwa, Takashi Aoi

    In the present study, we successfully generated lung cancer stem cell (CSC)-like cells by introducing a small set of transcription factors into a lung cancer cell line. In addition to properties that are conventionally referred to as CSC properties, the lung induced CSCs exhibited the ability to form lung cancer-like tissues in vitro with vascular cells and mesenchymal stem cells, which showed structures and immunohistological patterns that were similar to human lung cancer tissues. We named them "lung cancer organoids". We found that interleukin-6 (IL-6), which was expressed in the lung induced CSCs, facilitates the formation of lung cancer organoids via the conversion of mesenchymal stem cells into alpha-smooth muscle actin (alpha SMA)-positive cells. Interestingly, the combination of anti-IL-6 antibody and cisplatin could destroy the lung cancer organoids, while cisplatin alone could not. Furthermore, IL-6 mRNA-positive cancer cells were found in clinical lung cancer samples. These results suggest that IL-6 could be a novel therapeutic target in lung cancer.

    NATURE PUBLISHING GROUP, Sep. 2017, SCIENTIFIC REPORTS, 7 (1), 12317, English

    [Refereed]

    Scientific journal

  • iPS細胞を巡る最新の動向と今後の研究展開 人工癌幹細胞と癌オルガノイドを用いた癌幹細胞研究

    AOI TAKASHI, 石田 諒, OGAWA HIROYUKI, AOI MICHIYO, KAKEJI YOSHIHIRO, MANIWA YOSHIMASA

    Jun. 2017, Cytometry Research, 27 (Suppl), 36, Japanese

    Research society

  • リプログラミングを応用したがん幹細胞研究 人工癌幹細胞と癌オルガノイドを用いた癌幹細胞研究

    AOI TAKASHI, 石田諒, OGAWA HIROYUKI, AOI MICHIYO

    May 2017, 組織培養研究, 36 (3), 86, Japanese

    Research society

  • 諫田泰成, 中村和昭, 山崎大樹, 片岡健, Aoi Takashi, 中川誠人, 藤井万紀子, 阿久津英憲, 末盛博文, 浅香勲, 中村幸夫, 小島肇, 関野祐子, 古江-楠田美保

    2017, 組織培養研究, 36 (2), 13 - 19, Japanese

    [Refereed]

    Scientific journal

  • Takao Hayakawa, Takashi Aoi, Christopher Bravery, Karin Hoogendoorn, Ivana Knezevic, Junichi Koga, Daisuke Maeda, Akifumi Matsuyama, James McBlane, Tomohiro Morio, John Petricciani, Mahendra Rao, Anthony Ridgway, Daisaku Sato, Yoji Sato, Glyn Stacey, Norihisa Sakamoto, Jean-Hugues Trouvin, Akihiro Umezawa, Masayuki Yamato, Kazuo Yano, Hiroyuki Yokote, Kentaro Yoshimatsu, Pierrette Zorzi-Morre

    Academic Press, 01 Jan. 2016, Biologicals, 44 (1), 51, English

    [Refereed]

    Scientific journal

  • Current issues on cancer stem cell researches

    IshidaR, KakejiY, Aoi Takashi

    2016, Cytometry Research, 26 (2), 7 - 13, Japanese

    [Refereed]

    Scientific journal

  • Takao Hayakawa, Takashi Aoi, Christopher Bravery, Karin Hoogendoorn, Ivana Knezevic, Junichi Koga, Daisuke Maeda, Akifumi Matsuyama, James McBlane, Tomohiro Morio, John Petricciani, Mahendra Rao, Anthony Ridgway, Daisaku Sato, Yoji Sato, Glyn Stacey, Norihisa Sakamoto, Jean-Hugues Trouvin, Akihiro Umezawa, Masayuki Yamato, Kazuo Yano, Hiroyuki Yokote, Kentaro Yoshimatsu, Pierrette Zorzi-Morre

    The regulation of human cell therapy products is a key factor in their development and use to treat human diseases. In that regard, there is a recognized need for a global effort to develop a set of common principles that may serve to facilitate a convergence of regulatory approaches to ensure the smooth and efficient evaluation of products. This conference, with experts from regulatory agencies, industry, and academia, contributed to the process of developing such a document.Elements that could form a minimum consensus package of requirements for evaluating human cell therapy products were the overall focus of the conference. The important regulatory considerations that are unique to human cell therapy products were highlighted.Sessions addressed specific points that are different from those of traditional biological/biotechnological protein products. Panel discussions complemented the presentations.The conference concluded that most of the current regulatory framework is appropriate for cell therapy, but there are some areas where the application of the requirements for traditional biologicals is inappropriate. In addition, it was agreed that there is a need for international consensus on core regulatory elements, and that one of the major international organizations should take the lead in formulating such a consensus document.

    Academic Press, 01 Sep. 2015, Biologicals, 43 (5), 283 - 297, English

    International conference proceedings

  • Takao Hayakawa, Takashi Aoi, Christopher Bravery, Karin Hoogendoorn, Ivana Knezevic, Junichi Koga, Daisuke Maeda, Akifumi Matsuyama, James McBlane, Tomohiro Morio, John Petricciani, Mahendra Rao, Anthony Ridgway, Daisaku Sato, Yoji Sato, Glyn Stacey, Norihisa Sakamoto, Jean-Hugues Trouvin, Akihiro Umezawa, Masayuki Yamato, Kazuo Yano, Hiroyuki Yokote, Kentaro Yoshimatsu, Pierrette Zorzi-Morre

    The regulation of human cell therapy products is a key factor in their development and use to treat human diseases. In that regard, there is a recognized need for a global effort to develop a set of common principles that may serve to facilitate a convergence of regulatory approaches to ensure the smooth and efficient evaluation of products. This conference, with experts from regulatory agencies, industry, and academia, contributed to the process of developing such a document. Elements that could form a minimum consensus package of requirements for evaluating human cell therapy products were the overall focus of the conference. The important regulatory considerations that are unique to human cell therapy products were highlighted. Sessions addressed specific points that are different from those of traditional biological/biotechnological protein products. Panel discussions complemented the presentations.

    ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD, Sep. 2015, BIOLOGICALS, 43 (5), 283 - 297, English

    [Refereed]

    Scientific journal

  • Takashi Aoi, Glyn Stacey

    In order to assure the quality and safety of future advanced cell therapies it is vital to ensure that source materials including the donor cells have been assessed and demonstrated as suitable for use in the development and manufacture of such new medicines. Here we provide a brief overview of the key issues in the delivery of quality controlled and safety tested seed stocks of human pluripotent stem cell lines to support stem cell research and the development of advanced cell therapies. We also reflect on the importance of national and internationally coordinated cell banking systems in this process in order to promote more efficient development of cell therapies.

    ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD, Sep. 2015, BIOLOGICALS, 43 (5), 399 - 401, English

    [Refereed]

    Scientific journal

  • γδT細胞を用いた前立腺癌に対するアデノウイルスベクターデリバリーシステムの開発

    長谷部 友紀, 小川 良雄, 直江 道夫, 冨士 幸蔵, 青井 貴之, 水口 裕之, 寺尾 秀治

    医学図書出版(株), May 2015, 泌尿器外科, 28 (臨増), 858 - 858, Japanese

    [Refereed]

  • アデノウイルスベクターデリバリーシステムの基礎的検討(Third report)

    直江 道夫, 長谷部 友紀, 寺尾 秀治, 水口 裕之, 青井 貴之, 冨士 幸蔵, 小川 良雄

    (一社)日本泌尿器科学会総会事務局, Apr. 2015, 日本泌尿器科学会総会, 103回, 667 - 667, Japanese

    [Refereed]

  • Application of iPSC technology to cancer treatment

    Nobu Oshima, Takashi Aoi

    Induced pluripotent stem cells (iPSCs) can be generated via reprogramming of somatic cells into pluripotent stem cells by introducing defined factors with appropriate culture conditions. iPSC5 have 4 key properties. iPSCs have pluripotency and self- renewal ability, which are properties in common with embryonic stem cells. Additionally, iPSCs can be generated from various donor individuals with particular characteristics and also from various types of cells in a single donor. Regarding the medical applications of the technology, the best use of iPSCs should be based on a better understanding of these properties in accdance to different purposes. At present, the technology has been applied in various research fields. In cancer research, the technology has been expected to be useful, especially in immunotherapy, disease modeling, drug development. Thus, iPSC technology is a promising tool even in the field. Continuous challenges raise the hope for the development of novel caner treatments using iPSC technologies in the future.

    Japanese Journal of Cancer and Chemotherapy Publishers Inc., 01 Feb. 2015, Japanese Journal of Cancer and Chemotherapy, 42 (2), 139 - 143, Japanese

    [Refereed]

  • Study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of human embryonic stem (-like) cells

    HayakawaT, Aoi Takashi, UmezawaA, OzawaK, SatoY, SawaY, MatsuyamaA, YamanakaS, YamatoM

    2015, Regenerative Therapy, 2, 109 - 122, English

    [Refereed]

    Scientific journal

  • Study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of autologous human somatic stem cells

    HayakawaT, Aoi Takashi, UmezawaA, OzawaK, SatoY, SawaY, MatsuyamaA, YamanakaS, YamatoM

    2015, Regenerative Therapy, 2, 57 - 69, English

    [Refereed]

    Scientific journal

  • Study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of autologous human induced pluripotent stem (-like) cells

    HayakawaT, Aoi Takashi, UmezawaA, OzawaK, SatoY, SawaY, MatsuyamaA, YamanakaS, YamatoM

    2015, Regenerative Therapy, 2, 81 - 94, English

    [Refereed]

    Scientific journal

  • Study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of allogenic human somatic stem cells

    HayakawaT, Aoi Takashi, UmezawaA, OzawaK, SatoY, SawaY, MatsuyamaA, YamanakaS, YamatoM

    2015, Regenerative Therapy, 2, 70 - 80, English

    [Refereed]

    Scientific journal

  • Study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of allogenic human induced pluripotent stem (-like) cells

    HayakawaT, Aoi Takashi, UmezawaA, OzawaK, SatoY, SawaY, MatsuyamaA, YamanakaS, YamatoM

    2015, Regenerative Therapy, 2, 95 - 108, English

    [Refereed]

    Scientific journal

  • 前立腺癌に対するγδT細胞を用いたアデノウイルスベクターデリバリーシステムの開発(Development of the adenovirus vector delivery system using γδT cells to prostate cancer cell)

    長谷部 友紀, 小川 良雄, 直江 道夫, 冨士 幸蔵, 青井 貴之, 水口 裕之, 寺尾 秀治

    日本癌学会, Sep. 2014, 日本癌学会総会記事, 73回, P - 1322, English

    [Refereed]

  • Nobu Oshima, Yasuhiro Yamada, Satoshi Nagayama, Kenji Kawada, Suguru Hasegawa, Hiroshi Okabe, Yoshiharu Sakai, Takashi Aoi

    Cancer stem cells (CSCs) are considered to be responsible for the dismal prognosis of cancer patients. However, little is known about the molecular mechanisms underlying the acquisition and maintenance of CSC properties in cancer cells because of their rarity in clinical samples. We herein induced CSC properties in cancer cells using defined factors. We retrovirally introduced a set of defined factors (OCT3/4, SOX2 and KLF4) into human colon cancer cells, followed by culture with conventional serum-containing medium, not human embryonic stem cell medium. We then evaluated the CSC properties in the cells. The colon cancer cells transduced with the three factors showed significantly enhanced CSC properties in terms of the marker gene expression, sphere formation, chemoresistance and tumorigenicity. We designated the cells with CSC properties induced by the factors, a subset of the transduced cells, as induced CSCs (iCSCs). Moreover, we established a novel technology to isolate and collect the iCSCs based on the differences in the degree of the dye-effluxing activity enhancement. The xenografts derived from our iCSCs were not teratomas. Notably, in contrast to the tumors from the parental cancer cells, the iCSC-based tumors mimicked actual human colon cancer tissues in terms of their immunohistological findings, which showed colonic lineage differentiation. In addition, we confirmed that the phenotypes of our iCSCs were reproducible in serial transplantation experiments. By introducing defined factors, we generated iCSCs with lineage specificity directly from cancer cells, not via an induced pluripotent stem cell state. The novel method enables us to obtain abundant materials of CSCs that not only have enhanced tumorigenicity, but also the ability to differentiate to recapitulate a specific type of cancer tissues. Our method can be of great value to fully understand CSCs and develop new therapies targeting CSCs.

    PUBLIC LIBRARY SCIENCE, Jul. 2014, PLOS ONE, 9 (7), e101735, English

    [Refereed]

    Scientific journal

  • 泌尿器科癌細胞株に対するγδT細胞を用いたアデノウイルスベクターデリバリーシステムの開発(Development of the adenovirus vector delivery system using γδT cells to urological cancer cell lines)

    長谷部 友紀, 小川 良雄, 直江 道夫, 冨士 幸蔵, 青井 貴之, 水口 裕之, 寺尾 秀治

    日本癌学会, Oct. 2013, 日本癌学会総会記事, 72回, 435 - 435, English

    [Refereed]

  • Bilada Bilican, Andrea Serio, Sami J. Barmada, Agnes Lumi Nishimura, Gareth J. Sullivan, Monica Carrasco, Hemali P. Phatnani, Clare A. Puddifoot, David Story, Judy Fletcher, In-Hyun Park, Brad A. Friedman, George Q. Daley, David J. A. Wyllie, Giles E. Hardingham, Ian Wilmut, Steven Finkbeiner, Tom Maniatis, Christopher E. Shaw, Siddharthan Chandran

    Egawa et al. recently showed the value of patient-specific induced pluripotent stem cells (iPSCs) for modeling amyotrophic lateral sclerosis in vitro. Their study and our work highlight the need for complementary assays to detect small, but potentially important, phenotypic differences between control iPSC lines and those carrying disease mutations.

    AMER ASSOC ADVANCEMENT SCIENCE, Jun. 2013, SCIENCE TRANSLATIONAL MEDICINE, 5 (188), 188lr2, English

    [Refereed]

  • Takayuki Kondo, Masashi Asai, Kayoko Tsukita, Yumiko Kutoku, Yutaka Ohsawa, Yoshihide Sunada, Keiko Imamura, Naohiro Egawa, Naoki Yahata, Keisuke Okita, Kazutoshi Takahashi, Isao Asaka, Takashi Aoi, Akira Watanabe, Kaori Watanabe, Chie Kadoya, Rie Nakano, Dai Watanabe, Kei Maruyama, Osamu Hori, Satoshi Hibino, Tominari Choshi, Tatsutoshi Nakahata, Hiroyuki Hioki, Takeshi Kaneko, Motoko Naitoh, Katsuhiro Yoshikawa, Satoko Yamawaki, Shigehiko Suzuki, Ryuji Hata, Shu-ichi Ueno, Tsuneyoshi Seki, Kazuhiro Kobayashi, Tatsushi Toda, Kazuma Murakami, Kazuhiro Irie, William L. Klein, Hiroshi Mori, Takashi Asada, Ryosuke Takahashi, Nobuhisa Iwata, Shinya Yamanaka, Haruhisa Inoue

    Oligomeric forms of amyloid-beta peptide (A beta) are thought to play a pivotal role in the pathogenesis of Alzheimer's disease (AD), but the mechanism involved is still unclear. Here, we generated induced pluripotent stem cells (iPSCs) from familial and sporadic AD patients and differentiated them into neural cells. A beta oligomers accumulated in iPSC-derived neurons and astrocytes in cells from patients with a familial amyloid precursor protein (APP)-E693 Delta mutation and sporadic AD, leading to endoplasmic reticulum (ER) and oxidative stress. The accumulated A beta oligomers were not proteolytically resistant, and docosahexaenoic acid (DHA) treatment alleviated the stress responses in the AD neural cells. Differential manifestation of ER stress and DHA responsiveness may help explain variable clinical results obtained with the use of DHA treatment and suggests that DHA may in fact be effective for a subset of patients. It also illustrates how patient-specific iPSCs can be useful for analyzing AD pathogenesis and evaluating drugs.

    CELL PRESS, Apr. 2013, CELL STEM CELL, 12 (4), 487 - 496, English

    [Refereed]

    Scientific journal

  • Takashi Aoi

    Induced pluripotent stem (iPS) cells are generated from somatic cells by introducing small sets of transcription factors. iPS cells demonstrate pluripotency and the ability to self-renew. In addition, iPS cells can be generated from donor individuals with particular characteristics. Based on these features, iPS cells are expected to be applicable in drug discovery, the study of disease mechanisms and cell therapy. From a technical point of view, "diversity" is the key word. At present, iPS cells can be derived using various techniques, resulting in diversity in the quality of iPS cells generated. Therefore, optimization of the derivation technology is one of the most important issues. Another "diversity" is in the propensities amongst iPS cell lines derived using similar techniques. Thus, strategies for selecting good quality lines remain to be established. Considering such technical hurdles, establishment of an iPS cell bank consisting of high quality and versatile iPS lines is a promising idea because of the merits of cost and quality control. Now, we are exploring relevant parameters for the quality control of banked cells. The challenges facing clinical application of iPS cells are new but not unprecedented. To realize clinical applications of iPS cells, we need to make these challenges clear and overcome them through partnership not only with industry, governments and universities, but also patients and society at large.

    PHARMACEUTICAL SOC JAPAN, Feb. 2013, YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 133 (2), 197 - 200, Japanese

    [Refereed]

  • Shin-Ichi Mae, Akemi Shono, Fumihiko Shiota, Tetsuhiko Yasuno, Masatoshi Kajiwara, Nanaka Gotoda-Nishimura, Sayaka Arai, Aiko Sato-Otubo, Taro Toyoda, Kazutoshi Takahashi, Naoki Nakayama, Chad A. Cowan, Takashi Aoi, Seishi Ogawa, Andrew P. McMahon, Shinya Yamanaka, Kenji Osafune

    A method for stimulating the differentiation of human pluripotent stem cells into kidney lineages remains to be developed. Most cells in kidney are derived from an embryonic germ layer known as intermediate mesoderm. Here we show the establishment of an efficient system of homologous recombination in human pluripotent stem cells by means of bacterial artificial chromosome-based vectors and single-nucleotide polymorphism array-based detection. This system allowed us to generate human-induced pluripotent stem cell lines containing green fluorescence protein knocked into OSR1, a specific intermediate mesoderm marker. We have also established a robust induction protocol for intermediate mesoderm, which produces up to 90% OSR1 + cells. These human intermediate mesoderm cells can differentiate into multiple cell types of intermediate mesoderm-derived organs in vitro and in vivo, thereby supplying a useful system to elucidate the mechanisms of intermediate mesoderm development and potentially providing a cell source for regenerative therapies of the kidney. © 2013 Macmillan Publishers Limited. All rights reserved.

    2013, Nature Communications, 4, 1367, English

    [Refereed]

    Scientific journal

  • Michio Naoe, Yoshio Ogawa, Yuki Hasebe, Kozo Fuji, Sanju Iwamoto, Hiroyuki Mizuguchi, Takashi Aoi, Shuji Terao

    Developing new treatments that reduce prostate cancer progression is important. Therapeutic efficacy of conventional gene therapy for metastatic prostate cancer is still low. Lower induction rate of naked genes into target cell is due to reduced expression of adenovirus receptor on cancer cell and also due to high seroprevalence of anti-Ad antibodies in adults. Therefore, efficient Ad carrier systems that circumvent these problems should be developed. Gamma-delta T cells have demonstrated high affinity to cancer cells. CD46, which leads to broad tropism in Ad35 vectors, is expressed in hematopoietic cells, including γδ T cells. In this study, we demonstrate the potential of γδ T cells as "vehicles" for transporting Ad5/F35 vectors and genes into cancer cells. © 2013 Naoe M, et al.

    2013, Journal of Cancer Science and Therapy, 5 (11), 384 - 390, English

    [Refereed]

    Scientific journal

  • Naohiro Egawa, Shiho Kitaoka, Kayoko Tsukita, Motoko Naitoh, Kazutoshi Takahashi, Takuya Yamamoto, Fumihiko Adachi, Takayuki Kondo, Keisuke Okita, Isao Asaka, Takashi Aoi, Akira Watanabe, Yasuhiro Yamada, Asuka Morizane, Jun Takahashi, Takashi Ayaki, Hidefumi Ito, Katsuhiro Yoshikawa, Satoko Yamawaki, Shigehiko Suzuki, Dai Watanabe, Hiroyuki Hioki, Takeshi Kaneko, Kouki Makioka, Koichi Okamoto, Hiroshi Takuma, Akira Tamaoka, Kazuko Hasegawa, Takashi Nonaka, Masato Hasegawa, Akihiro Kawata, Minoru Yoshida, Tatsutoshi Nakahata, Ryosuke Takahashi, Maria C. N. Marchetto, Fred H. Gage, Shinya Yamanaka, Haruhisa Inoue

    Amyotrophic lateral sclerosis (ALS) is a late-onset, fatal disorder in which the motor neurons degenerate. The discovery of new drugs for treating ALS has been hampered by a lack of access to motor neurons from ALS patients and appropriate disease models. We generate motor neurons from induced pluripotent stem cells (iPSCs) from familial ALS patients, who carry mutations in Tar DNA binding protein-43 (TDP-43). ALS patient-specific iPSC-derived motor neurons formed cytosolic aggregates similar to those seen in postmortem tissue from ALS patients and exhibited shorter neurites as seen in a zebrafish model of ALS. The ALS motor neurons were characterized by increased mutant TDP-43 protein in a detergent-insoluble form bound to a spliceosomal factor SNRPB2. Expression array analyses detected small increases in the expression of genes involved in RNA metabolism and decreases in the expression of genes encoding cytoskeletal proteins. We examined four chemical compounds and found that a histone acetyltransferase inhibitor called anacardic acid rescued the abnormal ALS motor neuron phenotype. These findings suggest that motor neurons generated from ALS patient-derived iPSCs may provide a useful tool for elucidating ALS disease pathogenesis and for screening drug candidates.

    AMER ASSOC ADVANCEMENT SCIENCE, Aug. 2012, SCIENCE TRANSLATIONAL MEDICINE, 4 (145), 145ra104, English

    [Refereed]

    Scientific journal

  • Masatoshi Kajiwara, Takashi Aoi, Keisuke Okita, Ryosuke Takahashi, Haruhisa Inoue, Naoya Takayama, Hiroshi Endo, Koji Eto, Junya Toguchida, Shinji Uemoto, Shinya Yamanaka

    Hepatocytes generated from human induced pluripotent stem cells (hiPSCs) are unprecedented resources for pharmaceuticals and cell therapy. However, the in vitro directed differentiation of human pluripotent stem cells into mature hepatocytes remains challenging. Little attention has so far been paid to variations among hiPSC lines in terms of their hepatic differentiation. In the current study, we developed an improved hepatic differentiation protocol and compared 28 hiPSC lines originated from various somatic cells and derived using retroviruses, Sendai viruses, or episomal plasmids. This comparison indicated that the origins, but not the derivation methods, may be a major determinant of variation in hepatic differentiation. The hiPSC clones derived from peripheral blood cells consistently showed good differentiation efficiency, whereas many hiPSC clones from adult dermal fibroblasts showed poor differentiation. However, when we compared hiPSCs from peripheral blood and dermal fibroblasts from the same individuals, we found that variations in hepatic differentiation were largely attributable to donor differences, rather than to the types of the original cells. These data underscore the importance of donor differences when comparing the differentiation propensities of hiPSC clones.

    NATL ACAD SCIENCES, Jul. 2012, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 109 (31), 12538 - 12543, English

    [Refereed]

    Scientific journal

  • Masanori Imamura, Takashi Aoi, Ako Tokumasu, Nathan Mise, Kuniya Abe, Shinya Yamanaka, Toshiaki Noce

    Pluripotent stem cells can be established by various methods, but they share several cytological properties, including germ cell differentiation in vitro, independently of their origin. Although mouse induced pluripotent stem (iPS) cells can produce functional gametes in vivo, it is still unclear whether or not they have the ability to produce presumptive germ cells in vitro. Here, we show that mouse iPS cells derived from adult hepatocytes were able to differentiate into presumptive germ cells marked by mouse vase homolog (Mvh) expression in feeder-free or suspension cultures. Embryoid body (EB) formation from iPS cells also induced the formation of round-shaped cells resembling immature oocytes. Mvh(+) cells formed clumps by co-aggregation with differentiation-supporting cells, and increased expression of germ cell markers was detected in these cell aggregates. Differentiation culture of presumptive germ cells from iPS cells could provide a conventional system for facilitating our understanding of the mechanisms underlying direct reprogramming and germline competency.

    WILEY-LISS, Sep. 2010, MOLECULAR REPRODUCTION AND DEVELOPMENT, 77 (9), 802 - 811, English

    [Refereed]

    Scientific journal

  • 正しい知識が捏造を防ぐ データを正確に解釈するための6つのポイント(No.6)分子生物学,生化学,細胞生物学における統計のポイント--医療統計学の専門家を交えた鼎談[含 Q&A(第5回)質問・コメントとそれに対する回答 大規模データ解析における問題点]

    山中 伸弥, 青井 貴之, 佐藤 俊哉

    Oct. 2009, 蛋白質核酸酵素, 54 (13), 1792 - 1803, Japanese

    [Refereed]

  • Kyoko Miura, Yohei Okada, Takashi Aoi, Aki Okada, Kazutoshi Takahashi, Keisuke Okita, Masato Nakagawa, Michiyo Koyanagi, Koji Tanabe, Mari Ohnuki, Daisuke Ogawa, Eiji Ikeda, Hideyuki Okano, Shinya Yamanaka

    We evaluated the teratoma-forming propensity of secondary neurospheres (SNS) generated from 36 mouse induced pluripotent stem (iPS) cell lines derived in 11 different ways. Teratoma-formation of SNS from embryonic fibroblast-derived iPS cells was similar to that of SNS from embryonic stem (ES) cells. In contrast, SNS from iPS cells derived from different adult tissues varied substantially in their teratoma-forming propensity, which correlated with the persistence of undifferentiated cells.

    NATURE PUBLISHING GROUP, Aug. 2009, NATURE BIOTECHNOLOGY, 27 (8), 743 - 745, English

    [Refereed]

    Scientific journal

  • Hyenjong Hong, Kazutoshi Takahashi, Tomoko Ichisaka, Takashi Aoi, Osami Kanagawa, Masato Nakagawa, Keisuke Okita, Shinya Yamanaka

    Induced pluripotent stem(iPS) cells can be generated from somatic cells by the introduction of Oct3/4 ( also known as Pou5f1), Sox2, Klf4 and c-Myc, in mouse(1-4) and in human(5-8). The efficiency of this process, however, is low(9). Pluripotency can be induced without c-Myc, but with even lower efficiency(10,11). A p53 (also known as TP53 in humans and Trp53 in mice) short-interfering RNA (siRNA) was recently shown to promote human iPS cell generation(12), but the specificity and mechanisms remain to be determined. Here we report that up to 10% of transduced mouse embryonic fibroblasts lacking p53 became iPS cells, even without the Myc retrovirus. The p53 deletion also promoted the induction of integration-free mouse iPS cells with plasmid transfection. Furthermore, in the p53-null background, iPS cells were generated from terminally differentiated T lymphocytes. The suppression of p53 also increased the efficiency of human iPS cell generation. DNA microarray analyses identified 34 p53-regulated genes that are common in mouse and human fibroblasts. Functional analyses of these genes demonstrate that the p53-p21 pathway serves as a barrier not only in tumorigenicity, but also in iPS cell generation.

    NATURE PUBLISHING GROUP, Aug. 2009, NATURE, 460 (7259), 1132 - U95, English

    [Refereed]

    Scientific journal

  • Improved Gene Transfer into Renal Carcinoma Cells Using Adenovirus Vector Containing RGD Motif

    Shuji Terao, Bishnu Acharya, Toru Suzuki, Takashi Aoi, Michio Naoe, Katsuyuki Hamada, Hiroyuki Mizuguchi, Akinobu Gotoh

    The transduction efficacy of adenovirus serotype 5 (Ad5) vector in human renal carcinoma cells is generally extremely low due to the non-expression of Coxsackie and adenoviral receptor (CAR). We investigated whether fiber-modified Ad vector containing an RGD motif in the HI loop of the Ad fiber knob could increase the transduction efficiency of Ad5 in human renal carcinoma cells in vitro. Materials and Methods: We examined both expressions of CAR, and alpha(v), beta(3) and beta(5) integrins, and the transduction efficacy of fiber-modified adenovirus vector in all cell lines. Results: The expression of CAR was lower and those of av and beta(3) integrins were higher in all cell lines compared with control cell line, KK47. The transduction efficacy of fiber-modified Ad vector increased by 125- to 1,800-fold compared with Ad5. Conclusion: The fiber-modified Ad vector may be useful to establish effective new gene therapy strategies for the treatment of renal cell carcinoma.

    INT INST ANTICANCER RESEARCH, Aug. 2009, ANTICANCER RESEARCH, 29 (8), 2997 - 3001, English

    [Refereed]

    Scientific journal

  • Takashi Aoi, Kojiro Yae, Masato Nakagawa, Tomoko Ichisaka, Keisuke Okita, Kazutoshi Takahashi, Tsutomu Chiba, Shinya Yamanaka

    Induced pluripotent stem ( iPS) cells have been generated from mouse and human fibroblasts by the retroviral transduction of four transcription factors. However, the cell origins and molecular mechanisms of iPS cell induction remain elusive. This report describes the generation of iPS cells from adult mouse hepatocytes and gastric epithelial cells. These iPS cell clones appear to be equivalent to embryonic stem cells in gene expression and are competent to generate germline chimeras. Genetic lineage tracings show that liver- derived iPS cells are derived from albumin-expressing cells. No common retroviral integration sites are found among multiple clones. These data suggest that iPS cells are generated by direct reprogramming of lineage- committed somatic cells and that retroviral integration into specific sites is not required.

    AMER ASSOC ADVANCEMENT SCIENCE, Aug. 2008, SCIENCE, 321 (5889), 699 - 702, English

    [Refereed]

    Scientific journal

  • Masato Nakagawa, Michiyo Koyanagi, Koji Tanabe, Kazutoshi Takahashi, Tomoko Ichisaka, Takashi Aoi, Keisuke Okita, Yuji Mochiduki, Nanako Takizawa, Shinya Yamanaka

    Direct reprogramming of somatic cells provides an opportunity to generate patient- or disease-specific pluripotent stem cells. Such induced pluripotent stem (iPS) cells were generated from mouse fibroblasts by retroviral transduction of four transcription factors: Oct3/4, Sox2, Klf4 and c-Myc(1). Mouse iPS cells are indistinguishable from embryonic stem (ES) cells in many respects and produce germline- competent chimeras(2-4). Reactivation of the c-Myc retrovirus, however, increases tumorigenicity in the chimeras and progeny mice, hindering clinical applications(3). Here we describe a modified protocol for the generation of iPS cells that does not require the Myc retrovirus. With this protocol, we obtained significantly fewer non-iPS background cells, and the iPS cells generated were consistently of high quality. Mice derived from Myc-iPS cells did not develop tumors during the study period. The protocol also enabled efficient isolation of iPS cells without drug selection. Furthermore, we generated human iPS cells from adult dermal fibroblasts without MYC.

    NATURE PUBLISHING GROUP, Jan. 2008, NATURE BIOTECHNOLOGY, 26 (1), 101 - 106, English

    [Refereed]

    Scientific journal

  • Tsutomu Chiba, Takashi Aoi

    BLACKWELL PUBLISHING, Jul. 2007, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 22 (7), 965 - 967, English

    [Refereed]

  • T Aoi, H Marusawa, T Sato, T Chiba, M Maruyama

    B M J PUBLISHING GROUP, Apr. 2006, GUT, 55 (4), 588 - 589, English

    [Refereed]

    Scientific journal

MISC

  • リプログラミング因子を用いた人工骨肉腫幹細胞株の樹立とその特性の探索

    藤原 周一, 河本 旭哉, 川上 洋平, 原 仁美, 深瀬 直政, 竹森 俊幸, 北山 和道, 八尋 俊輔, 青井 貴之, 黒田 良祐, 秋末 敏宏

    (公社)日本整形外科学会, Sep. 2019, 日本整形外科学会雑誌, 93 (8), S1679 - S1679, Japanese

  • リプログラミング因子を用いた人工骨肉腫幹細胞株の樹立とその特性の探索

    藤原周一, 河本旭哉, 川上洋平, 原仁美, 深瀬直政, 竹森俊幸, 北山和道, 八尋俊輔, 青井貴之, 黒田良祐, 秋末敏宏

    (公社)日本整形外科学会, Sep. 2019, 日本整形外科学会雑誌, 93 (8), S1679 - S1679, Japanese

  • リプログラミング因子を用いた人工骨肉腫幹細胞株の樹立

    藤原 周一, 河本 旭哉, 川上 洋平, 小寺澤 康文, 原 仁美, 深瀬 直政, 竹森 俊幸, 北山 和道, 秋末 敏宏, 青井 貴之, 黒田 良祐

    (公社)日本整形外科学会, Jun. 2019, 日本整形外科学会雑誌, 93 (6), S1416 - S1416, Japanese

  • リプログラミング因子を用いた人工骨肉腫幹細胞株の樹立

    藤原周一, 河本旭哉, 河本旭哉, 川上洋平, 小寺澤康文, 小寺澤康文, 小寺澤康文, 原仁美, 深瀬直政, 竹森俊幸, 北山和道, 秋末敏宏, 秋末敏宏, 青井貴之, 青井貴之, 黒田良祐

    (公社)日本整形外科学会, Jun. 2019, 日本整形外科学会雑誌, 93 (6), S1416 - S1416, Japanese

  • ENHANCED DIFFERENTIATION AND STRATIFICATION OF BLADDER UROTHELIUM FROM HUMAN INDUCED PLURIPOTENT STEM CELL

    Kotaro Suzuki, Michiyo Koyanagi-Aoi, Keiichiro Uehara, Nobuyuki Hinata, Masato Fujisawa, Takashi Aoi

    LIPPINCOTT WILLIAMS & WILKINS, Apr. 2019, JOURNAL OF UROLOGY, 201 (4), E155 - E156, English

    Summary international conference

  • 下垂体発生における視床下部-口腔外胚葉間FGFの役割

    松本 隆作, 青井 貴之, 小柳 三千代, 須賀 英隆, 福岡 秀規, 井口 元三, 小川 渉, 高橋 裕

    (一社)日本内分泌学会, Apr. 2019, 日本内分泌学会雑誌, 95 (1), 352 - 352, Japanese

  • 下垂体発生における視床下部-口腔外胚葉間FGFの役割

    松本 隆作, 青井 貴之, 小柳 三千代, 須賀 英隆, 福岡 秀規, 井口 元三, 小川 渉, 高橋 裕

    (一社)日本内分泌学会, Apr. 2019, 日本内分泌学会雑誌, 95 (1), 408 - 408, Japanese

  • 下垂体発生における視床下部-口腔外胚葉間FGFの役割

    松本 隆作, 青井 貴之, 小柳 三千代, 須賀 英隆, 福岡 秀規, 井口 元三, 小川 渉, 高橋 裕

    (一社)日本内分泌学会, Apr. 2019, 日本内分泌学会雑誌, 95 (1), 408 - 408, Japanese

  • 下垂体発生における視床下部-口腔外胚葉間FGFの役割

    松本 隆作, 青井 貴之, 小柳 三千代, 須賀 英隆, 福岡 秀規, 井口 元三, 小川 渉, 高橋 裕

    (一社)日本内分泌学会, Apr. 2019, 日本内分泌学会雑誌, 95 (1), 352 - 352, Japanese

  • 転写因子OTX2は視床下部からのFGFシグナルを介して下垂体を分化させる

    松本 隆作, 須賀 英隆, 井口 元三, 福岡 秀規, 長谷川 奉延, 六車 恵子, 小川 渉, 青井 貴之, 高橋 裕

    (一社)日本内分泌学会, Apr. 2018, 日本内分泌学会雑誌, 94 (1), 314 - 314, Japanese

  • 【iPS細胞技術を駆使したがん、感染症のあらたな制御】 同種iPS細胞由来γδT細胞を用いたがん免疫療法の可能性

    Aoi Takashi

    Dec. 2017, 医学のあゆみ, 263 (11-12号), 915 - 919, Japanese

    Introduction commerce magazine

  • 疾患特異的iPS細胞を用いた先天性下垂体機能低下症の病態解明

    松本 隆作, 須賀 英隆, 青井 貴之, 坂東 弘教, 福岡 秀規, 井口 元三, 鳴海 覚志, 高木 優樹, 石井 智弘, 長谷川 奉延, 六車 恵子, 小川 渉, 高橋 裕

    (一社)日本内分泌学会, Apr. 2017, 日本内分泌学会雑誌, 93 (1), 249 - 249, Japanese

  • In vitro Construction of Lung Cancer Organoids from Induced Lung Cancer Stem Like Cells

    Hiroyuki Ogawa, Takashi Aoi, Nahoko Shimizu, Daisuke Hokka, Yugo Tanaka, Michiyo Koyanagi-Aoi, Yoshimasa Maniwa

    ELSEVIER SCIENCE INC, Jan. 2017, JOURNAL OF THORACIC ONCOLOGY, 12 (1), S1153 - S1153, English

    Summary international conference

  • Takashi Aoi

    At present, most cases of unresectable cancer cannot be cured. Genetic mutations, EMT, and cancer stem cells are three major issues linked to poor prognosis in such cases, all connected by inter- and intra-tumor heterogeneity. Issues on inter-/intra-tumor heterogeneity of genetic mutation could be resolved with recent and future technologies of deep sequencers, whereas, regarding such issues as the “same genome, different epigenome/phenotype”, we expect to solve many of these problems in the future through further research in stem cell biology. We herein review and discuss the three major issues in the biology of cancers, especially from the standpoint of stem cell biology.

    Springer Tokyo, 01 Sep. 2016, General Thoracic and Cardiovascular Surgery, 64 (9), 517 - 523, English

    Book review

  • Takashi Aoi

    In 2006, induced pluripotent stem (iPS) cells were generated by Yamanaka and Takahashi for the first time from a mouse fibroblast culture by introducing four factors. In the 10 years since then, this breakthrough discovery has been making waves in the fields of biology and medical science. For example, various technologies for generating iPS cells have been developed, and we have cultivated a better understanding of the mechanisms involved in reprogramming. In addition, many researchers have explored the applications of iPS cells, such as drug discovery, the study of disease mechanisms and regenerative medicine, and the development of advanced technologies for the differentiation and qualification of the cells. Furthermore, the concept of iPS cell generation has inspired a number of studies that do not use iPS cells. We herein review and discuss the past, present and future of iPS cells and their related issues.

    OXFORD UNIV PRESS, Sep. 2016, JOURNAL OF BIOCHEMISTRY, 160 (3), 121 - 129, English

    Book review

  • 疾患特異的iPS細胞を用いた下垂体疾患の病態解明

    松本 隆作, 須賀 英隆, 福岡 秀規, 井口 元三, 小武 由紀子, 吉田 健一, 坂東 弘教, 隅田 健太郎, 西沢 衡, 高木 優樹, 石井 智弘, 長谷川 奉延, 六車 恵子, 青井 貴之, 小川 渉, 高橋 裕

    (一社)日本内分泌学会, Apr. 2016, 日本内分泌学会雑誌, 92 (1), 300 - 300, Japanese

  • Takao Hayakawa, Takashi Aoi, Christopher Bravery, Karin Hoogendoorn, Ivana Knezevic, Junichi Koga, Daisuke Maeda, Akifumi Matsuyama, James McBlane, Tomohiro Morio, John Petricciani, Mahendra Rao, Anthony Ridgway, Daisaku Sato, Yoji Sato, Glyn Stacey, Norihisa Sakamoto, Jean-Hugues Trouvin, Akihiro Umezawa, Masayuki Yamato, Kazuo Yano, Hiroyuki Yokote, Kentaro Yoshimatsu, Pierrette Zorzi-Morre

    ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD, Jan. 2016, BIOLOGICALS, 44 (1), 51 - 51, English

    Others

  • 石田諒, Kakeji Yoshihiro, 青井貴之

    2016, Cytometry research, 26 (2), 7 - 13, Japanese

    [Refereed]

    Introduction scientific journal

  • 【再生医療-新たな医療を求めて-】 臨床応用を目指した基礎研究 多能性幹細胞とreprogramming技術 ヒト多能性幹細胞株の分化特性とばらつき

    青井三千代, 小柳, Aoi Takashi

    Jun. 2015, 日本臨床, 73 (増刊5 再生医療), 74 - 79, Japanese

    Introduction scientific journal

  • Generation of induced cancer stem cells from human colon cancer cells by somatic cell reprogramming factors

    Nobu Oshima, Yoshiharu Sakai, Takashi Aoi

    ELSEVIER SCIENCE INC, Oct. 2014, JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 219 (4), E120 - E120, English

    Summary international conference

  • Retrovirus Insertion in iPSCs Identifies Genes Facilitating Somatic Reprogramming

    Ali Nowrouzi, Takashi Aoi, Friederike Herbst, Annette Deichmann, Anne Arens, Nergis Kara, Philipp K. Zimmermann, Claudia R. Ball, Ulrich Abel, Jochen Utikal, Glimm Hanno, Schmidt Manfred, Yamanaka Shinya, Christof von Kalle

    NATURE PUBLISHING GROUP, May 2014, MOLECULAR THERAPY, 22, S15 - S15, English

    Summary international conference

  • Masatoshi Kajiwara, Takashi Aoi, Keisuke Okita, Ryosuke Takahashi, Haruhisa Inoue, Naoya Takayama, Hiroshi Endo, Koji Eto, Junya Toguchida, Shinji Uemoto, Shinya Yamanaka

    NATL ACAD SCIENCES, Sep. 2012, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 109 (36), 14716 - 14716, English

    Others

  • Japanese guidelines on ensuring quality and safety of products derived from engineered human stem cells-after public consultation-

    T. Hayakawa, T. Aoi, A. Umezawa, K. Ozawa, Y. Sato, Y. Sawa, A. Matsuyama, S. Yamanaka, M. Yamato

    WILEY-BLACKWELL, Sep. 2012, JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE, 6, 407 - 408, English

    Summary international conference

  • gamma delta T Cell Transports Adenovirus Vector for Prostate Cancer Cells

    M. Naoe, Y. Ogawa, Y. Hasebe, T. Suzuki, T. Aoi, H. Mizuguchi, S. Terao

    ELSEVIER SCIENCE INC, Sep. 2012, UROLOGY, 80 (3), S277 - S277, English

    Summary international conference

  • Comprehensive Analyses of Chimeras and Progeny Mice from Induced Pluripotent Stem Cells

    Aoi, T, Okita, K, Ichisaka, T, Nakagawa, M, Koyanagi, M, Tanabe, K, Takahashi, K, Yamanaka, S

    Jun. 2012, ISSCR 10th annual Meeting, English

    [Refereed]

  • iPS細胞-樹立培養方法

    青井貴之, 大貫茉里, 沖田圭介

    2012, 実験医学別冊 目的別で選べる細胞培養プロトコール, 210 - 228, Japanese

    [Invited]

    Introduction commerce magazine

  • 「ヒト幹細胞を用いた細胞・組織加工医薬品等の品質及び安全性確保に関する研究(その1)ヒト幹細胞を用いた細胞・組織加工医薬品等の品質・安全性確保に関する指針整備と主なポイント」

    早川堯夫, 青井貴之, 梅澤明弘, 小澤敬也, 佐藤陽治, 澤芳樹, 松山晃文, 大和雅之, 山中伸弥

    2011, 10 (3), 206 - 210

  • 「ヒト幹細胞を用いた細胞・組織加工医薬品等の品質及び安全性確保に関する研究(その2)ヒト(自己)体性幹細胞加工医薬品等の品質及び安全性の確保に関する指針(案)」

    早川堯夫, 青井貴之, 梅澤明弘, 小澤敬也, 佐藤陽治, 澤芳樹, 松山晃文, 大和雅之, 山中伸弥

    2011, 再生医療, 10 (3), 211 - 218

  • 「ヒト幹細胞を用いた細胞・組織加工医薬品等の品質及び安全性確保に関する研究(その3)ヒト(同種)体性幹細胞加工医薬品等の品質及び安全性の確保に関する指針(案)」

    早川堯夫, 青井貴之, 梅澤明弘, 小澤敬也, 佐藤陽治, 澤芳樹, 松山晃文, 大和雅之, 山中伸弥

    2011, 再生医療, 10 (3), 219 - 226

  • 「ヒト幹細胞を用いた細胞・組織加工医薬品等の品質及び安全性確保に関する研究(その4)ヒト(自己)iPS(様)細胞加工医薬品等の品質及び安全性の確保に関する指針(案)」

    早川堯夫, 青井貴之, 梅澤明弘, 小澤敬也, 佐藤陽治, 澤芳樹, 松山晃文, 大和雅之, 山中伸弥

    2011, 再生医療, 10 (3), 227 - 237

  • 「ヒト幹細胞を用いた細胞・組織加工医薬品等の品質及び安全性確保に関する研究(その5)ヒト(同種)iPS(様)細胞加工医薬品等の品質及び安全性の確保に関する指針(案)」

    早川堯夫, 青井貴之, 梅澤明弘, 小澤敬也, 佐藤陽治, 澤芳樹, 松山晃文, 大和雅之, 山中伸弥

    2011, 再生医療, 10 (3), 238 - 248

  • 「ヒト幹細胞を用いた細胞・組織加工医薬品等の品質及び安全性確保に関する研究(その6)ヒトES細胞加工医薬品等の品質及び安全性の確保に関する指針(案)」

    早川堯夫, 青井貴之, 梅澤明弘, 小澤敬也, 佐藤陽治, 澤芳樹, 松山晃文, 大和雅之, 山中伸弥

    2011, 再生医療, 10 (3), 249 - 260

  • 「ヒト幹細胞を用いた細胞・組織加工医薬品等の品質及び安全性確保に関する研究(その7)ヒト幹細胞加工医薬品等の品質及び安全性の確保に関する指針(案)―ヒト体性幹細胞、iPS(様)細胞又はES細胞を加工して製造される医薬品等(ヒト幹細胞加工医薬品等)の最終製品の品質管理―」

    早川堯夫, 青井貴之, 梅澤明弘, 小澤敬也, 佐藤陽治, 澤芳樹, 松山晃文, 大和雅之, 山中伸弥

    2011, 再生医療, 10 (3), 261 - 266

  • 「ヒト幹細胞を用いた細胞・組織加工医薬品等の品質及び安全性確保に関する研究(その8)―ヒト体性幹細胞、iPS(様)細胞又はES細胞を加工して製造される医薬品等(ヒト幹細胞加工医薬品等)の非臨床試験及び臨床試験について―」

    早川堯夫, 青井貴之, 梅澤明弘, 小澤敬也, 佐藤陽治, 澤芳樹, 松山晃文, 大和雅之, 山中伸弥

    2011, 再生医療, 10 (3), 267 - 272

  • microRNAの発現プロファイリングのiPS細胞の安全性/質の評価系への応用

    小柳三千代, 一阪朋子, 成田恵, 青井貴之, 沖田圭介, 高橋和利, 山中伸弥

    2010, 生化学, ROMBUNNO.4P-0900, Japanese

  • Chromosomal instability of various human iPS cell clones using high-resolution DNA analysis.

    OTSUKA AKIKO, AOI TAKASHI, OKITA KEISUKE, TAKAHASHI KAZUTOSHI, MTSUBARA AIKO, KAWAMATA SHIN, OGAWA SEISHI, YAMANAKA SHINYA

    2010, 生化学, ROMBUNNO.4P-0899, English

  • microRNA 発現プロファイリングiPS 細胞評価系への応用

    小柳三千代, 一阪朋子, 成田恵, 田邊剛士, 三浦恭子, 青井貴之, 沖田圭介, 高橋和利, 中川誠人, 山中伸弥

    2010, 第9 回日本再生医療医学会総会(2010.3.18 広島) ※ポスター発表, Japanese

    [Refereed]

  • microRNAs are actively involved in induction of pluripotent stem cells from mouse and human fibroblasts

    KOYANAGI MICHIYO, ICHISAKA TOMOKO, OKADA AKI, NARITA MEGUMI, TANABE KOJI, AOI TAKASHI, OKITA KEISUKE, TAKAHASHI KAZUTOSHI, NAKAGAWA MASATO, YAMANAKA SHINYA

    2009, 日本分子生物学会年会講演要旨集, 32nd (Vol.2), 190, English

  • Comprehensive analyses of chimeras and progeny mice from induced pluripotent stem cells

    青井貴之, 沖田圭介, 一阪朋子, 中川誠人, 小柳三千代, 八戸宏二郎, 田邊剛士, 高橋和利, 山中伸弥

    2009, 第32 回日本分子生物学会 年会(2009.12.10 横浜)※ポスター発表, Japanese

    [Refereed]

  • Long term observation of iPS cells-derived mice.

    Aoi T, Okita K, Ichisaka T, Tanabe K, Koyanagi M, Takahashi K, Nakagawa M, Yamanaka S

    2009, 7th ISSCR Annual Meeting (2009.7.9 Spain)※ポスター発表, English

    [Refereed]

  • Increased generation efficiency of induced pluripotent stem cell by suppression of p53 in mouse and human.

    Hong H, Takahashi K, Ichisaka T, Aoi T, Nakagawa M, Okita K, Yamanaka S

    2009, 7th ISSCR Annual Meeting (2009.7.10 Spain)※ポスター発表, English

    [Refereed]

  • iPS 細胞に由来するマ Annual Report 2008 ウスの長期経過観察

    青井貴之, 沖田圭介, 一阪朋子, 田邊剛士, 小柳三千代, 高橋和利, 中川誠人, 山中伸弥

    2008, 独立行政法人科学技術振興機構「免役難病・感染症等の先進医療技術」第5回公開シン ポジウム(2008.12.15.東京)※ポスター発表, Japanese

    [Refereed]

  • 人工多能性幹細胞におけるレトロウイルス挿入部位の解析

    八戸宏二郎, 青井貴之, 沖田圭介, 高橋和利, 中川誠人, 山中伸弥

    2007, 生化学, 2P-1162, Japanese

  • 成体マウスからの生殖系列に分化可能な人工多能性幹細胞誘導

    青井貴之, 一阪朋子, 高橋和利, 沖田圭介, 中川誠人, 山中伸弥

    2007, 生化学, 2P-1161, Japanese

  • Generation of high quality iPS cells

    Takahashi K, Okita K, Nakagawa M, Aoi T, Ichisaka T, Yamanaka S

    2007, Neuro2007(第30 回日本神経科学大会,第50 回日本神経化学会大会,第17 回日本神経回路学会大会合同学会)(2007.9.12.横浜), English

    [Refereed]

  • マウス体細胞の初期化に関わるmicroRNA の探索とその機能解析

    小柳三千代, 青井貴之, 沖田圭介, 高橋和利, 中川誠人, 山中伸弥

    2007, BMB2007(第30 回日本分子生物学会年会 第80 回日本生化学会大会 合同大会) (2007.12.12.神奈川), Japanese

    [Refereed]

Books etc

  • Gene Therapy and Cell Therapy Through the Liver-Current Aspects and Future Prospects / The Way to Clinical Applications of Human Pluripotent Stem Cells

    Aoi Takashi

    Others, Springer, 2015, English

    Scholarly book

  • 実験医学別冊「ES・iPS細胞実験スタンダード」

    青井 貴之

    Joint work, 羊土社, Mar. 2014

  • 再生医療用語ハンドブック

    青井 貴之

    Joint work, 株式会社メディカルトリビューン, 2014

  • 腎と透析 特集「幹細胞研究と再生医療」

    青井 貴之

    Joint work, 東京医学社, Dec. 2013

  • 週刊 医学のあゆみ「iPS細胞技術を駆使したがん、感染症のあらたな制御」

    青井 貴之

    Joint work, 医学のあゆみ

  • バイオロジクスの開発と品質・安全性確保 「iPS細胞の特性解析、品質・安全性確保」

    青井 貴之

    Joint work

  • iPS時代の幹細胞最前線

    青井 貴之

    Joint work, 株式会社化学同人

Presentations

  • iPS細胞、ES細胞

    青井 貴之

    日本消化器病学会再生医療研究推進委員会セミナー ~再生医療 up to date~, 10 Jul. 2021, Japanese

    Public discourse

  • 機械学習を用いたiPS細胞からの下垂体オルガノイド分化効率予測モ デルの作成

    松本 隆作, 須賀 英隆, 青井 貴之, 高橋 裕, 山本 拓也

    第94回日本内分泌学会学術総会, Japanese

    Oral presentation

  • 下垂体腫瘍オルガノイド樹立への挑戦

    藤田 泰功, 志智 大城, 福岡 秀規, 浦井 伸, 蟹江 慶太郎, 山本 雅昭, 井口 元三, 青井 貴之, 谷口 理章, 山田 正三, 小川 渉, 髙橋 裕

    第31回日本間脳下垂体腫瘍学会, Japanese

  • Differentiation of human induced pluripotent stem cells into testosterone producing Leydig-like cells

    青井 貴之

    2021 China-Japan Workshop on Cell & Gene Therapy, 25 Feb. 2021

  • 新しいがん治療

    青井 貴之

    がん臨床試験専門職養成セミナー, 13 Feb. 2021, Japanese

    Public discourse

  • ヒトiPS細胞を用いた膀胱尿路上皮細胞の 分化誘導と膀胱再建

    鈴木光太郎, 青井貴之, 藤澤正人

    第108回日本泌尿器科学会総会, 23 Dec. 2020, Japanese

    Nominated symposium

  • 幹細胞・再生医学イノベーション創出プログラム

    青井 貴之

    AMED再生・細胞医療・遺伝子治療研究交流会・シンポジウム, 21 Dec. 2020, Japanese

    Nominated symposium

  • iPS細胞研究のアップデートと将来展望

    青井 貴之

    AMED再生・細胞医療・遺伝子治療研究交流会・シンポジウム, 21 Dec. 2020, Japanese

    Nominated symposium

  • Cancer Research applying Cell Fate Manipulation Technologies

    Takashi Aoi

    5th DIA Cell and Gene Therapy Products Symposium in Japan, 10 Dec. 2020, English

    [Invited]

    Public discourse

  • 細胞バンク、細胞特性解析

    青井 貴之

    第5回DIA再生医療製品・遺伝子治療用製品シンポジウム, 10 Dec. 2020, Japanese

    Public discourse

  • 再生医療研究の現状と未来

    青井 貴之

    日本人類遺伝学会第65回大会, 18 Nov. 2020, Japanese

    Public discourse

  • A New Method to Generate Osteosarcoma Cells with Cancer Stem Cell Properties by Reprogramming Factors

    Shuichi Fujiwara, Teruya Kawamoto, Hitomi Hara, Yohei Kawakami, Kazumichi Kitayama, Shunsuke Yahiro, Yasufumi Koterazawa, Toshihiro Akisue, Takashi Aoi, Ryosuke Kuroda

    ORS 2020 Annual Meeting, 11 Feb. 2020

    Poster presentation

  • 新しいがん治療

    青井貴之

    がん専門CRC養成セミナー, 08 Feb. 2020

    [Invited]

    Public discourse

  • Sustainable availability of qualified raw materials for manufacturing of hCTPs

    Takashi Aoi

    5th IABS Cell Therapy Conference in Tokyo, 04 Feb. 2020

    [Invited]

    Nominated symposium

  • 再生医療から考える医療のこれから

    青井貴之

    第14回聖ルカ・アカデミア, 25 Jan. 2020

    [Invited]

    Public discourse

  • iPS細胞を用いる医学の展開

    青井 貴之

    第44回日本小児皮膚科学会学術大会, 19 Jan. 2020, Japanese

    Public discourse

  • ヒトiPS細胞からのγδT細胞誘導

    村井信幸, 青井貴之, 野村正, 橋川和信, 寺師浩人

    第28回日本形成外科学会基礎学術集会, 14 Nov. 2019

    Oral presentation

  • 細胞の運命を操る技術の医学応用

    青井貴之

    第23回CCM輸液・栄養研究会, 02 Nov. 2019

    [Invited]

    Invited oral presentation

  • リプログラミング因子を用いた人工骨肉腫幹細胞株の樹立

    藤原周一, 河本旭哉, 原仁美, 川上洋平, 北山和道, 八尋俊輔, 小寺澤康文, 青井貴之, 黒田良祐, 秋末敏宏

    第34回日本整形外科学会基礎学術集会, 17 Oct. 2019

    Poster presentation

  • 幹細胞操作技術を用いた細胞と組織の科学

    青井貴之

    第60回日本組織細胞化学総会・学術集会, 19 Sep. 2019

    [Invited]

  • Challenges to Regenerative Medicine in Japan

    Takashi Aoi

    Stem Cell Symposium, 29 Aug. 2019

    [Invited]

    Public discourse

  • リプログラミング因子を用いた人工骨肉腫幹細胞株の樹立

    藤原周一, 河本旭哉, 原仁美, 深瀬直政, 川上洋平, 竹森俊幸, 北山和道, 小寺澤康文, 秋末敏宏, 青井貴之, 黒田良祐

    第52回日本整形外科学会骨・軟部腫瘍学術集会, 12 Jul. 2019

    Poster presentation

  • iPSが切り拓く未来,

    青井貴之

    日本外科代謝栄養学会第56回学術集会, 05 Jul. 2019

    [Invited]

    Invited oral presentation

  • 幹細胞生物学の医学への展開

    青井貴之

    あじさい会, 22 Jun. 2019

    [Invited]

    Public discourse

  • ヒト iPS細胞由来テストステロン産生Leydig細胞によるラット低テストステロン血症の改善

    石田 貴樹, FUJISAWA MASATO, AOI TAKASHI

    第16回泌尿器科再建再生研究科, 08 Jun. 2019, Japanese, Domestic conference

    Oral presentation

  • ATRAはヒトiPS細胞から食道への分化誘導を促進する

    小寺澤 康文, 小柳 三千代, KAKEJI YOSHIHIRO, AOI TAKASHI

    第73回食道学会学術集会, 07 Jun. 2019, Japanese, Domestic conference

    Poster presentation

  • iPS細胞の基本と免疫形質

    青井貴之

    第8回神戸免疫組織診断セミナー, 26 May 2019

    [Invited]

    Public discourse

  • iPS細胞、ES細胞

    青井貴之

    日本消化器病学会School of Regenerative Medicine for Digestive Diseases, 25 May 2019

    Public discourse

  • 下垂体発生における視床下部-口腔外胚葉間FGFの役割

    松本隆作, 青井 貴之, 小柳三千代, 須賀英隆, 福岡秀規, 井口元三, 小川渉, 高橋裕

    第92回 日本内分泌学会学術総会, 11 May 2019

    Oral presentation

  • Enhanced differentiation and stratification of bladder urothelium from human induced pluripotent stem cell.

    Suzuk K, Koyanagi-Aoi M, Uehara K, Hinata N, Fujisawa M, Aoi T

    The American Urological Association's 2019 Annual Meeting, 03 May 2019

    Oral presentation

  • ヒト iPS細胞由来テストステロン産生Leydig細胞によるラット低テストステロン血症の改善

    石田貴樹, 藤澤正人, 青井貴之

    第107回日本泌尿器科学会総会, 20 Apr. 2019

    Oral presentation

  • ヒトiPS細胞から尿路上皮への分化誘導における重層化の促進

    鈴木 光太郎, FUJISAWA MASATO, AOI TAKASHI

    第107回日本泌尿器科学会総会, 18 Apr. 2019, Japanese, Domestic conference

    Poster presentation

  • 疾患特異的iPS細胞を用いた先天性下垂体形成不全病態モデル作成

    松本 隆作, 須賀 英隆, AOI MICHIYO, 鳴海 覚志, 長谷川 奉延, 六車 恵子, AOI TAKASHI, 髙橋 裕

    第18回 日本再生医療学会総会, Mar. 2019, Japanese, 神戸, Domestic conference

    Oral presentation

  • リプログラミング因子を用いた人工骨肉腫幹細胞株の樹立

    藤原 周一, KAWAMOTO TERUYA, 川上 洋平, 小寺澤 康文, HARA HITOMI, 深瀬 直政, 竹森 俊幸, 北山 和道, AKISUE TOSHIHIRO, AOI TAKASHI, KURODA RYOSUKE

    第18回日本再生医療学会総会, Mar. 2019, Japanese, 神戸, Domestic conference

    Poster presentation

  • ヒトiPS細胞から尿路上皮への分化誘導における重層化の促進

    鈴木 光太郎, AOI MICHIYO, FUJISAWA MASATO, AOI TAKASHI

    第18回日本再生医療学会総会, Mar. 2019, Japanese, 神戸, Domestic conference

    Poster presentation

  • Human induced pluripotent stem cell-derived testosterone-producing Leydig cells ameliorate serum testosterone level in rats.

    Takaki Ishida, Masato Fujisawa, Takashi Aoi

    34th Annual EAU Congress, Mar. 2019, English, Barcelona, International conference

    Poster presentation

  • Directed differentiation of feeder-free human induced pluripotent stem cells into stratified bladder urothelium

    鈴木 光太郎, AOI MICHIYO, UEHARA KEIICHIRO, HINATA NOBUYUKI, AOI TAKASHI, FUJISAWA MASATO

    The 34th Annual EAU Congress, Mar. 2019, English, バルセロナ, International conference

    Poster presentation

  • Directed differentiation of feeder-free human induced pluripotent stem cells into stratified bladder urothelium

    Kotaro Suzuki, Michiyo Koyanagi-Aoi, Keiichiro Uehara, Nobuyuki Hinata, Masato Fujisawa, Takashi Aoi

    34th Annual EAU Congress, Mar. 2019, English, Barcelona, International conference

    Poster presentation

  • CO2インキュベーター内におけるコンタミネーションリスクの検討

    多田 光輝, 古川 悠, AOI TAKASHI

    第18回日本再生医療学会総会, Mar. 2019, Japanese, 神戸, Domestic conference

    Poster presentation

  • 再生医療の現状と課題、展望について

    AOI TAKASHI

    イーピーエス株式会社 社内講演会, Feb. 2019, Japanese, 東京, Domestic conference

    Public discourse

  • リプログラミング因子を用いた人工骨肉腫幹細胞株の樹立

    藤原 周一, KAWAMOTO TERUYA, 川上 洋平, 小寺澤 康文, HARA HITOMI, 深瀬 直政, 竹森 俊幸, 北山 和道, AKISUE TOSHIHIRO, AOI TAKASHI, KURODA RYOSUKE

    第2回日本サルコーマ治療研究学会学術集会, Feb. 2019, Japanese, 日本サルコーマ治療研究学会, 東京, Domestic conference

    Poster presentation

  • Development of Induced Osteosarcoma Stem Cells Using Induced Pluripotent Stem (iPs) Cells Production Technology

    Shuichi Fujiwara, Teruya Kawamoto, Naomasa Fukase, Hitomi Hara, Yohei Kawakami, Toshiyuki Takemori, Kazumichi Kitayama, Takashi Aoi, Ryosuke Kuroda, Toshihiro Akisue

    The 65th Annual Meeting of Orthopaedic Research Society, Feb. 2019, English, Orthopaedic Research Society, Austin, Domestic conference

    Poster presentation

  • Enhanced differentiation and stratification ofbladder urothelium from human induced pluripotent stem cell

    Kotaro Suzuki, Michiyo Koyanagi-Aoi, Keiichiro Uehara, Nobuyuki Hinata, Masato Fujisawa, Takashi Aoi

    the American Urological Association's 2019 Annual Meeting, 2019, English, International conference

    Oral presentation

  • 安全な「再生医療」を患者さんに届けるための科学とそれ以外のこと

    AOI TAKASHI

    「リスクとコミュニケーションのモデル構築事業」市民講座, Dec. 2018, Japanese, 盛岡, Domestic conference

    Public discourse

  • ヒトiPS細胞由来ホルモン産生Leydig細胞の作製

    石田 貴樹, FUJISAWA MASATO, AOI TAKASHI

    第21回 日本生殖内分泌学会学術集会, Dec. 2018, Japanese, 福岡, Domestic conference

    Oral presentation

  • ガン細胞に抗ガン剤を製造させる新規治療法の開発

    西村香音, 山本翔太, AOI TAKASHI, Maruyama Tatsuo

    若手フロンティア研究会2018, Dec. 2018, Japanese, 神戸大学研究基盤センター, 神戸市, Domestic conference

    Poster presentation

  • Supramolecular hydrogels composed of D-oligopeptides for 3-dimensional (3D) cell culture

    Witta Kartika Restu, Shota Yamamoto, Yuki Nishida, Takashi Aoi, Maruyama Tatsuo

    1st GLowing Polymer Symposium in KANTO, Dec. 2018, English, 高分子学会, Tokyo, International conference

    Oral presentation

  • Selective cytotoxicity of enzyme-responsive peptide lipids containing tyrosine residues

    西村香音, 山本翔太, AOI TAKASHI, Maruyama Tatsuo

    IPC2018, Dec. 2018, English, 高分子学会, 広島市, International conference

    Poster presentation

  • iPS細胞を応用した医学研究の展開

    AOI TAKASHI

    平成30年度日本医師会生涯教育講座, Dec. 2018, Japanese, 新潟, Domestic conference

    Public discourse

  • iPS細胞が拓いた医学の展開

    AOI TAKASHI

    芦屋市健やかな会一般公開講座, Nov. 2018, Japanese, 神戸, Domestic conference

    Public discourse

  • 「再生医療」への期待へ科学はどうこたえられるか?

    AOI TAKASHI

    「リスクとコミュニケーションのモデル構築事業」市民講座, Oct. 2018, Japanese, 愛媛, Domestic conference

    Public discourse

  • iPS細胞の臨床応用:現状と課題

    AOI TAKASHI

    第55回日本糖尿病学会近畿地方会・第54回日本糖尿病協会近畿地方会, Oct. 2018, Japanese, 神戸, Domestic conference

    [Invited]

    Invited oral presentation

  • 細胞を選択的に殺傷するチロシン含有ペプチド脂質の開発

    西村香音, 山本翔太, AOI TAKASHI, Maruyama Tatsuo

    化学工学会第50回秋季大会, Sep. 2018, Japanese, 化学工学会, 鹿児島市, Domestic conference

    Poster presentation

  • 酵素応答性ペプチド脂質の細胞毒性の評価

    西村香音, 山本翔太, AOI TAKASHI, Maruyama Tatsuo

    第67回高分子討論会, Sep. 2018, Japanese, 高分子学会, 札幌市, Domestic conference

    Poster presentation

  • 医療の明日に向けて

    AOI TAKASHI

    神戸医療産業都市20周年事業記念イベント, Sep. 2018, Japanese, 神戸, Domestic conference

    Public discourse

  • Human induced pluripotent stem cell-derived testosterone-producing Leydig cells ameliorate serum testosterone level in rats

    石田 貴樹, FUJISAWA MASATO, AOI TAKASHI

    第29回 日本性機能学会学術総会, Sep. 2018, English, 神戸, Domestic conference

    Oral presentation

  • 疾患特異的iPS細胞を用いた下垂体形成不全の病態解明

    松本 隆作, 須賀 英隆, AOI TAKASHI, 六車 恵子, 長谷川 奉延, OGAWA WATARU, 髙橋 裕

    糖尿病・内分泌疾患ジャンプアップセミナー, Aug. 2018, Japanese, 神戸, Domestic conference

    Oral presentation

  • 細胞運命操作技術の医学応用

    AOI TAKASHI

    神戸薬科大学特別研究セミナー, Aug. 2018, Japanese, 神戸, Domestic conference

    Public discourse

  • 摂食障害による男性低ゴナドトロピン性性腺機能低下症の1例

    石田 貴樹, 田中 幹人, 角井 健太, 福田 輝雄, 江夏 徳寿, CHIBA KOJI, MATSUSHITA KEI, NAKANO YUZO, FUJISAWA MASATO, AOI TAKASHI

    第18回 日本Men'sHealth医学会, Jul. 2018, Japanese, 東京, Domestic conference

    Poster presentation

  • ガン細胞を選択的に殺傷するペプチド脂質の開発

    西村香音, 山本翔太, AOI TAKASHI, Maruyama Tatsuo

    第64回高分子研究発表会(神戸), Jul. 2018, Japanese, 高分子学会, 神戸市, Domestic conference

    Poster presentation

  • Selective cytotoxicity of tyrosine-containing peptide lipids

    Kanon NISHIMURA, Shota YAMAMOTO, Takashi AOI, Maruyama Tatsuo

    MACRO 2018 World Polymer Congress, Jul. 2018, English, MACRO 2018, Cairns, International conference

    Poster presentation

  • iPS細胞研究の現状と新しい癌治療の展望

    AOI TAKASHI

    アフラック神戸総合アソシエイツ会, Jul. 2018, Japanese, 神戸, Domestic conference

    Public discourse

  • 幹細胞技術の創薬への展開

    AOI TAKASHI

    神戸ポートアイランド創薬フォーラム, Jun. 2018, Japanese, 神戸, Domestic conference

    Public discourse

  • ヒトiPS細胞由来テストステロン産生Leydig細胞によるラット低テストステロン血症の改善

    石田 貴樹, FUJISAWA MASATO, AOI TAKASHI

    第37回 日本アンドロロジー学会, Jun. 2018, Japanese, 神戸, Domestic conference

    Oral presentation

  • ヒトiPS細胞からの成熟した尿路上皮への高効率な分化誘導

    鈴木 光太郎, AOI TAKASHI, FUJISAWA MASATO

    第15回泌尿器科再建再生研究会, Jun. 2018, Japanese, 沖縄, Domestic conference

    Oral presentation

  • ガン細胞に選択的な毒性を発揮する酵素応答性ペプチド脂質の開発

    西村香音, 山本翔太, AOI TAKASHI, Maruyama Tatsuo

    第7回 JACI/GSCシンポジウム, Jun. 2018, Japanese, 新化学技術推進協会, 神戸市, Domestic conference

    Poster presentation

  • iPS細胞・細胞運命操作・癌

    AOI TAKASHI

    兵庫県保険医協会 第50回総会記念講演, Jun. 2018, Japanese, 神戸, Domestic conference

    Public discourse

  • iPS細胞がインスパイアした医学の展開

    AOI TAKASHI

    第114回日本精神神経学会学術総会, Jun. 2018, Japanese, 神戸, Domestic conference

    Oral presentation

  • 再生医療の最近の動向と神戸大学における幹細胞研究の5年

    AOI TAKASHI

    味の素㈱講演会, May 2018, Japanese, 川崎, Domestic conference

    Public discourse

  • ヒトips細胞を用いた膵内分泌細胞への分化誘導

    山田 瑞姫, ASAHARA SHUNICHIROU, 遠山 春希, 下野 名奈子, 原 瑞希, 田中 孝一, 松田 友和, KIMURA MAKI, 神野 歩, 高井 智子, 鈴木 江美, AOI TAKASHI, KIDO YOSHIAKI

    第61回日本糖尿病学会年次学術集会, May 2018, Japanese, 東京, Domestic conference

    Others

  • チロシン含有ペプチド脂質の細胞毒性の評価

    西村香音, 山本翔太, AOI TAKASHI, Maruyama Tatsuo

    第67回高分子学会年次大会, May 2018, Japanese, 高分子学会, 名古屋市, Domestic conference

    Poster presentation

  • PI3-キナーゼ遺伝子異常による インスリン抵抗症の同定と iPS細胞を用いた障害の解析

    浜口 哲矢, HIROTA YUSHI, 松本 真明, AWANO HIROYUKI, IIJIMA KAZUMOTO, SATAKE WATARU, TODA TATSUSHI, AOI MICHIYO, AOI TAKASHI, OGAWA WATARU

    第61回日本糖尿病学会年次学術集会, May 2018, Japanese, 東京, Domestic conference

    Oral presentation

  • Human induced pluripotent stem cell-derived testosterone-producing Leydig cells ameliorate serum testosterone level in rats

    Takaki Ishida, Masato Fujisawa, Takashi Aoi

    The 113th American Urological Association, May 2018, English, San Francisco, International conference

    Oral presentation

  • 転写因子OTX2は視床下部からのFGFシグナルを介して下垂体を分化させる

    松本 隆作, 須賀 英隆, IGUCHI GENZO, FUKUOKA HIDENORI, 長谷川 奉延, 六車 恵子, OGAWA WATARU, AOI TAKASHI, 髙橋 裕

    第91回 日本内分泌学会学術総会, Apr. 2018, Japanese, 宮崎, Domestic conference

    Oral presentation

  • ヒトiPS細胞由来Leydig細胞の作製

    石田 貴樹, FUJISAWA MASATO, AOI TAKASHI

    第106回日本泌尿器科学会総会, Apr. 2018, Japanese, 京都, Domestic conference

    Oral presentation

  • Human induced pluripotent stem cell-derived testosterone-producing Leydig cells ameliorate serum testosterone level in rats

    石田 貴樹, FUJISAWA MASATO, AOI TAKASHI

    第106回日本泌尿器科学会総会, Apr. 2018, English, 京都, Domestic conference

    Oral presentation

  • 培養細胞に対するペプチド脂質の毒性評価

    西村香音, 山本翔太, AOI TAKASHI, Maruyama Tatsuo

    化学工学会第20回化学工学会学生発表会, Mar. 2018, Japanese, 化学工学会, 東広島市, Domestic conference

    Oral presentation

  • Perspectives in the Achievement of Regenerative Medicine Research

    Aoi Takashi

    International Symposium/Workshop on Bioethics Governance, Mar. 2018, English, 滋賀大学, 滋賀, International conference

    [Invited]

    Nominated symposium

  • CPFの費用削減と交差汚染を抑制できる半開放型気流制御ブースの開発

    多田光輝, 長谷川雅一, 古川悠, 松尾恵倫子, Aoi Takashi

    第17回日本再生医療学会総会, Mar. 2018, Japanese, 日本再生医療学会, 横浜, Domestic conference

    Poster presentation

  • Differentiation of hormone-producing Leydig cells from human iPS cells

    石田 貴樹, Fujisawa Masato, Aoi Takashi

    International Society for Sexual Medicine 2018, Feb. 2018, English, International Society for Sexual Medicine, Lisbon, Portugal, International conference

    [Invited]

    Nominated symposium

  • iPS細胞にインスパイアされた医学の展開

    Aoi Takashi

    平成29年度第2ブロック研修会, Jan. 2018, Japanese, 高槻市医師会, 大阪, Domestic conference

    Public discourse

  • 人工がん幹細胞と癌オルガノイドを用いたがん幹細胞研究の展開

    Aoi Takashi

    平成29年度第5回再生医療サポートビジネス懇話会, Dec. 2017, Japanese, 京都リサーチパーク株式会社, 京都, Domestic conference

    Public discourse

  • 細胞培養時の困りごと~CO2インキュベーターを中心に~

    Aoi Takashi

    細胞プロセス情報交換会~作業時の困りごとについて~, Dec. 2017, Japanese, ダイダン株式会社, 神奈川, Domestic conference

    Public discourse

  • Establishment of trophoblast-like cells from human iPS cells by induced expression of CDX2

    下出 紗弓, 宮沢 孝幸, Aoi Takashi

    ConBio2017, Dec. 2017, Japanese, The Molecular Biology Society of Japan, 神戸, Domestic conference

    Poster presentation

  • ヒトiPS細胞を用いた膵内分泌細胞への分化誘導法の確立

    山田 瑞姫, ASAHARA SHUNICHIROU, 下野 名奈子, 田中 孝一, 松田 友和, KIMURA MAKI, 神野 歩, 高井 智子, 鈴木 江美, AOI TAKASHI, KIDO YOSHIAKI

    第40回日本分子生物学会年会, Dec. 2017, Japanese, 神戸, Domestic conference

    Poster presentation

  • Applications of cell fate engineering

    Aoi Takashi

    US-Japan Symposium on Drug Delivery Systems, Dec. 2017, English, Massachusetts Institute of Technology, Maui, Hawaii, International conference

    [Invited]

    Invited oral presentation

  • 人工癌幹細胞と癌オルガノイドを用いた癌幹細胞研究

    Aoi Takashi

    第5回細胞凝集研究会, Nov. 2017, Japanese, 岡山理科大学, 岡山, Domestic conference

    [Invited]

    Nominated symposium

  • 疾患特異的iPS細胞を用いたLHX4異常症の病態解明

    松本 隆作, 須賀 英隆, Aoi Takashi, 高木 優樹, 長谷川 奉延, 六車 恵子, Ogawa Wataru, Takahashi Yutaka

    第27回内分泌代謝Update, Nov. 2017, Japanese, 日本内分泌学会, 神戸, Domestic conference

    Poster presentation

  • 疾患特異的iPS細胞を用いたLHX4異常症の病態解明

    松本 隆作, 須賀 英隆, Aoi Takashi, 高木 優樹, 長谷川 奉延, 六車 恵子, Ogawa Wataru, Takahashi Yutaka

    第27回臨床内分泌代謝Update, Nov. 2017, Japanese, 臨床内分泌代謝Update, 神戸, Domestic conference

    Oral presentation

  • ヒトiPS細胞由来テストステロン産生Leydig細胞の作製

    石田 貴樹, Fujisawa Masato, Aoi Takashi

    第67回 日本泌尿器科学会中部総会, Nov. 2017, Japanese, 日本泌尿器科学会, 大阪, Domestic conference

    [Invited]

    Nominated symposium

  • ヒトiPS細胞由来テストステロン産生Leydig細胞の作製

    石田 貴樹, Fujisawa Masato, Aoi Takashi

    第63回日本生殖医学会学術講演会, Nov. 2017, Japanese, 日本生殖医学会, 山口, Domestic conference

    Oral presentation

  • iPS細胞のいま、再生医療のこれから

    Aoi Takashi

    「リスクとコミュニケーションのモデル構築事業」市民講座, Nov. 2017, Japanese, 日本再生医療学会, 岩手, Domestic conference

    Public discourse

  • Disease modeling of congenital pituitary hypoplasia and the clarification of underlying mechanisms using patient-derived induced pluripotent stem cell

    松本 隆作, 須賀 英隆, Aoi Takashi, 長谷川 奉延, 六車 恵子, OGAWA WATARU, Takahashi Yutaka

    CiRA 2017 International symposium, Nov. 2017, English, CiRA 2017 International symposium, Kyoto, Japan, International conference

    Poster presentation

  • 人工肺癌幹細胞を用いた、肺癌組織再構築と新規治療法開発の試み

    Ogawa Hiroyuki, Aoi Michiyo, Aoi Takashi, Maniwa Yoshimasa

    第58回日本肺癌学会学術集会, Oct. 2017, Japanese, 日本肺癌学会, 横浜, Domestic conference

    Oral presentation

  • 疾患特異的iPS細胞を用いた先天性下垂体機能低下症の病態解明

    松本 隆作, Aoi Takashi, 須賀 英隆, 長谷川 奉延, 六車 恵子, Ogawa Wataru, Takahashi Yutaka

    第5回神緑会YIA発表会, Oct. 2017, Japanese, 神緑会, 神戸, Domestic conference

    Poster presentation

  • 神戸大学における再生医学研究

    Aoi Takashi

    平成29年度 第3回神戸再生医療勉強会, Sep. 2017, Japanese, 先端医療振興財団, 神戸, Domestic conference

    Public discourse

  • 細胞運命の操作技術の医学応用

    Aoi Takashi

    第267回がん研有明病院学術研究講演会, Sep. 2017, Japanese, がん研有明病院, 東京, Domestic conference

    Public discourse

  • 細胞の運命を操る技術とその応用

    Aoi Takashi

    第14回日本フットケア学会神戸セミナー, Sep. 2017, Japanese, 日本フットケア学会, 神戸, Domestic conference

    [Invited]

    Invited oral presentation

  • Induced hormone-producing Leydig cells derived from human iPS cells

    石田 貴樹, Fujisawa Masato, Aoi Takashi

    CiRA 2017, Sep. 2017, English, Center for iPS Cell Research and Application,Kyouto University, 京都, Domestic conference

    Poster presentation

  • iPS細胞を応用した医学研究の展開

    Aoi Takashi

    日本泌尿器科学会東部総会, Sep. 2017, Japanese, 日本泌尿器科学会, 東京, Domestic conference

    Keynote oral presentation

  • 細胞の運命を変える技術を使った医学研究

    Aoi Takashi

    日本赤十字社和歌山医療センター学術講演会, Aug. 2017, Japanese, 日本赤十字社和歌山医療センター, 和歌山, Domestic conference

    Public discourse

  • 人工癌幹細胞と癌オルガノイドを用いた癌幹細胞研究

    Aoi Takashi

    日本組織培養学会第90回大会, Jul. 2017, Japanese, 日本組織培養学会, 岡山, Domestic conference

    [Invited]

    Nominated symposium

  • 疾患特異的iPS細胞を用いた先天性下垂体低形成の 病態解明(シンポジウム・ワークショップパネル)

    松本 隆作, Aoi Takashi, 須賀 英隆, Takahashi Yutaka

    第5回下垂体スキルアップセミナー, Jul. 2017, Japanese, /, 神戸, Domestic conference

    [Invited]

    Nominated symposium

  • 疾患特異的iPS細胞を用いた先天性下垂体低形成の 病態解明

    松本 隆作, Aoi Takashi, 須賀 英隆, Takahashi Yutaka

    第5回下垂体スキルアップセミナー, Jul. 2017, Japanese, /, 神戸, Domestic conference

    [Invited]

    Invited oral presentation

  • ヒトiPS細胞由来テストステロン産生Leydig細胞の作製

    石田 貴樹, Fujisawa Masato, Aoi Takashi

    第22回 日本生殖内分泌学会学術集会, Jul. 2017, Japanese, 日本生殖内分泌学会, 沖縄, Domestic conference

    Oral presentation

  • ヒトiPS細胞の医療応用研究の現状

    Aoi Takashi

    中央医業経営研究会総会, Jul. 2017, Japanese, 中央医業経営研究会, 神戸, Domestic conference

    Public discourse

  • 人工癌幹細胞と癌オルガノイドを用いた癌幹細胞研究

    Aoi Takashi, 石田 諒, Ogawa Hiroyuki, Aoi Michiyo, Kakeji Yoshihiro, Maniwa Yoshimasa

    第27回日本サイトメトリー学会学術集会, Jun. 2017, Japanese, 日本サイトメトリー学会, 神戸, Domestic conference

    [Invited]

    Nominated symposium

  • ヒトiPS細胞誘導Leydig細胞の作製

    石田 貴樹, Fujisawa Masato, Aoi Takashi

    日本アンドロロジー学会第36回学術総会, Jun. 2017, Japanese, 日本アンドロジー学会, 倉敷, Domestic conference

    Oral presentation

  • ヒトiPS細胞由来テストステロン産生Leydig細胞の作製

    石田 貴樹, Fujisawa Masato, Aoi Takashi

    第14回 泌尿器科再建再生研究会, Jun. 2017, Japanese, 泌尿器科再建再生研究会, 東京, Domestic conference

    Oral presentation

  • 人工肺癌幹細胞による、肺癌組織再構築の試み

    Ogawa Hiroyuki, Shimizu Nahoko, Hokka Daisuke, Tanaka Yugo, Aoi Michiyo, Aoi Takashi, Maniwa Yoshimasa

    第34回日本呼吸器外科学会総会, May 2017, Japanese, 日本呼吸器外科学会, 福岡, Domestic conference

    Oral presentation

  • Induced hormone-producing Leydig cells derived from human iPS cells

    石田 貴樹, Fujisawa Masato, Aoi Takashi

    International Congress of Andrology 2017, May 2017, English, International Congress of Andrology, Copenhagen, Denmark, International conference

    [Invited]

    Invited oral presentation

  • ヒトIps細胞を用いた2型糖尿病発症機序の解明

    下野 名奈子, ASAHARA SHUNICHIROU, 原 瑞季, 田中 孝一, 松田 友和, KIMURA MAKI, 神野 歩, 高井 智子, 鈴木 江美, AOI TAKASHI, KIDO YOSHIAKI

    第60回日本糖尿病学会年次学術集会, May 2017, Japanese, 名古屋, Domestic conference

    Poster presentation

  • Development of iPSC-based γδT-cell Immunotherapy for Digestive Cancer

    渡邉 大輔, Azuma Takeshi, Aoi Takashi

    Digestive Disease Week 2017, May 2017, English, The American Gastroenterological Association, シカゴ, USA, International conference

    Poster presentation

  • 疾患特異的iPS細胞を用いた先天性下垂体機能低下症の病態解明

    松本 隆作, 須賀 英隆, Aoi Takashi, 坂東 弘教, Fukuoka Hidenori, Iguchi Genzo, 鳴海 覚志, 高木 優樹, 石井 智弘, 長谷川 奉延, 六車 恵子, Ogawa Wataru, Takahashi Yutaka

    第90回日本内分泌学会学術総会, Apr. 2017, Japanese, 日本内分泌学会, 京都, Domestic conference

    Oral presentation

  • Induce Human iPS cells into Leydig cells secrete androgen

    石田 貴樹, Fujisawa Masato, Aoi Takashi

    第105回 日本泌尿器科学会総会, Apr. 2017, English, 日本泌尿器科学会, 鹿児島, Domestic conference

    Oral presentation

  • Service for Self -私のかたちをつくるしくみ-

    Aoi Takashi

    神戸ロータリークラブ例会, Apr. 2017, Japanese, 神戸ロータリークラブ, 神戸, Domestic conference

    Public discourse

  • Interleukin-6 blockade, a novel cancer stem cell targeted therapy, attenuates lung cancer tissue construction.

    Ogawa Hiroyuki, Aoi Michiyo, Aoi Takashi, Maniwa Yoshimasa

    American Association for Cancer Research annual meeting 2017, Apr. 2017, English, American Association for Cancer Research, Washington D.C., USA, International conference

    Poster presentation

  • ヒトiPS細胞由来ホルモン産生Leydig細胞の作製

    石田 貴樹, 田中 幹人, 角井 健太, 福田 輝雄, Enatsu Noritoshi, Chiba Koji, Matsushita Kei, Nakano Yuzo, Fujisawa Masato, Aoi Takashi

    第12回 日本生殖再生医学会, Mar. 2017, Japanese, 日本生殖再生医学会, 東京, Domestic conference

    Oral presentation

  • ヒトiPS細胞を用いたACTH産生細胞成熟機構の解析とin vitro腫瘍モデル作成の試み

    松本 隆作, 須賀 英隆, Aoi Takashi, Fukuoka Hidenori, Iguchi Genzo, 小武 由紀子, 吉田 健一, 坂東 弘教, 隅田 健太郎, 西沢 衡, Ogawa Wataru, Takahashi Yutaka

    第27回間脳下垂体腫瘍学会, Feb. 2017, Japanese, 日本間脳下垂体腫瘍学会, 東京, Domestic conference

    Oral presentation

  • ヒトiPS細胞由来ホルモン産生Leydig細胞の作製(ポスター発表)

    石田 貴樹, 田中 幹人, 角井 健太, 福田 輝雄, Enatsu Noritoshi, Chiba Koji, Matsushita Kei, Nakano Yuzo, Fujisawa Masato, Aoi Takashi

    第21回 日本生殖内分泌学会学術集会, Jan. 2017, Japanese, 日本生殖内分泌学会, 大阪, Domestic conference

    Poster presentation

  • ヒトiPS細胞由来ホルモン産生Leydig細胞の作製

    石田 貴樹, 田中 幹人, 角井 健太, 福田 輝雄, Enatsu Noritoshi, Chiba Koji, Matsushita Kei, Nakano Yuzo, Fujisawa Masato, Aoi Takashi

    第21回 日本生殖内分泌学会学術集会, Jan. 2017, Japanese, 日本生殖内分泌学会, 大阪, Domestic conference

    Oral presentation

  • In vitro construction of lung cancer organoids from induced lung cancer stem like cells.

    Ogawa Hiroyuki, Shimizu Nahoko, Hokka Daisuke, Tanaka Yugo, 小柳(青井, 三千代, Aoi Takashi, 真庭 謙昌

    The 17th World Conference on Lung Cancer., Dec. 2016, English, IASLC, Vienna, Austria, International conference

    Poster presentation

  • ヒトips細胞を用いた2型糖尿病原因遺伝子による糖尿病発症機序の解明

    下野 名奈子, 淺原 俊一郎, 原 瑞季, 田中 孝一, 松田 友和, 木村 真希, 神野 歩, 高井 智子, 鈴木 江美, Aoi Takashi, Kido Yoshiaki

    第39回日本分子生物学会年会, Nov. 2016, Japanese, 日本分子生物学会, 横浜, Domestic conference

    Poster presentation

  • iPS細胞由来Vγ9Vδ2T細胞を用いる新規消化器がん治療法の開発

    渡邉 大輔, Azuma Takeshi, Aoi Takashi

    JDDW2016, Nov. 2016, English, 一般社団法人 日本消化器関連学会機構, 神戸, Domestic conference

    Poster presentation

  • Applications of iPS cell technology for Gastroenterology and Hepatology

    Aoi Takashi

    APDW2016, Nov. 2016, English, 日本消化器外科学会, 神戸, Domestic conference

    [Invited]

    Invited oral presentation

  • 10th Anniversary of iPS Cells

    Aoi Takashi

    JAACT2016, Nov. 2016, English, 日本動物細胞工学会, 神戸, Domestic conference

    [Invited]

    Invited oral presentation

  • iPS細胞の医学応用

    Aoi Takashi

    第117回日本結核病学会近畿地方会・第87回日本呼吸器学会, Jul. 2016, Japanese, 日本結核病学会・日本呼吸器学会, 大阪, Domestic conference

    [Invited]

    Invited oral presentation

  • 体細胞初期化因子導入による肺癌幹細胞誘導

    Ogawa Hiroyuki, Hokka Daisuke, Tanaka Yugo, Aoi Takashi, Maniwa Yoshimasa

    第33回日本呼吸器外科学会, May 2016, Japanese, 日本呼吸器外科学会, 京都, Domestic conference

    Oral presentation

  • 体細胞初期化因子導入による肺癌幹細胞誘導

    Ogawa Hiroyuki, Hokka Daisuke, Tanaka Yugo, Aoi Takashi, 真庭 謙昌

    第33回日本呼吸器外科学会総会, May 2016, Japanese, 日本呼吸器外科学会, 京都, Domestic conference

    Poster presentation

  • 疾患特異的iPS細胞を用いた下垂体疾患の病態解明

    松本 隆作, 須賀 英隆, Fukuoka Hidenori, Iguchi Genzo, 小武 由紀子, 吉田 健一, 坂東 弘教, 隅田 健太郎, 西澤 衡, 高木 優樹, 石井 智弘, 長谷川 奉延, 六車 恵子, Aoi Takashi, Ogawa Wataru, Takahashi Yutaka

    第89回日本内分泌学会学術総会, Apr. 2016, Japanese, 日本内分泌学会, 京都, Domestic conference

    Poster presentation

  • 再生医療の実施における現段階と課題

    Aoi Takashi

    「生命倫理ガバナンス」国際シンポジウム・ワークショップ, Mar. 2016, Japanese, 公益財団法人 上廣倫理財団研究, 京都, Domestic conference

    [Invited]

    Nominated symposium

  • iPS細胞~知恵と工夫で新たな挑戦~

    Aoi Takashi

    カワサキ協栄会第二分科会, Feb. 2016, Japanese, ダンロップグッドイヤータイヤ株式会社, 明石, Domestic conference

    Public discourse

  • iPS細胞開発から10年~臨床医学への展開~

    Aoi Takashi

    平成27年度 第56回総合プログラム, Feb. 2016, Japanese, 大阪大学歯学部同窓会兵庫県支部, 神戸, Domestic conference

    Public discourse

  • iPS細胞から10年-臨床医学への展開-

    Aoi Takashi

    神戸・内科疾患研究会, Jan. 2016, Japanese, アステラス製薬株式会社, 神戸, Domestic conference

    Public discourse

  • 再生医療の新時代に求められる技術革新

    Aoi Takashi

    ダイダンプレミアムセミナー, Nov. 2015, Japanese, ダイダン株式会社, 東京, Domestic conference

    Public discourse

  • iPS細胞研究の現状と展望

    Aoi Takashi

    第15回日本先進糖尿病治療研究会, Nov. 2015, Japanese, 日本先進糖尿病治療研究会, 京都, Domestic conference

    Public discourse

  • iPS細胞研究の現状と課題

    Aoi Takashi

    神戸医科大学昭和40年卒50周年記念, Nov. 2015, Japanese, 神緑会, 神戸, Domestic conference

    [Invited]

    Nominated symposium

  • 肺癌の生物学的特性-上皮間葉転換、癌幹細胞、遺伝子変異

    Aoi Takashi

    第68回日本胸部外科学会定期学術集会, Oct. 2015, Japanese, 日本胸部外科学会, 神戸, Domestic conference

    Oral presentation

  • 特定因子の導入による肺癌幹細胞の誘導と、その上皮間葉転換、浸潤への関与

    小川 裕行, Tane Shinya, Hokka Daisuke, Tanaka Yugo, Aoi Takashi, 真庭 謙昌

    第68回日本胸部外科学会 定期学術集会, Oct. 2015, Japanese, 日本胸部外科学会, 神戸, Domestic conference

    Oral presentation

  • iPS細胞研究の展開

    Aoi Takashi

    神戸大学クラブ(KUC)講演会, Aug. 2015, Japanese, 神戸大学クラブ, 神戸, Domestic conference

    Public discourse

  • 特定因子の導入による人工大腸癌幹細胞の誘導

    石田 諒, 大嶋 野歩, Kakeji Yoshihiro, Aoi Takashi

    第25回日本サイトメトリー学会学術集会, Jul. 2015, Japanese, 日本サイトメトリー学会, 東京, Domestic conference

    Oral presentation

  • iPS細胞から10年:次の時代のイノベーションに向けて

    Aoi Takashi

    神戸大学 グローバル新時代 ビジネスシンポジウム, Jul. 2015, Japanese, 神戸大学, 大阪, Domestic conference

    [Invited]

    Nominated symposium

  • iPS細胞研究の展開

    Aoi Takashi

    第43回日本血管外科学会学術総会, Jun. 2015, Japanese, 日本血管外科学会, 横浜, Domestic conference

    Oral presentation

  • 科学の明日へ向けて ~せせらぎ澄みて~

    Aoi Takashi

    九州保健福祉大学生命医科学部開設​記念講演, May 2015, Japanese, 学校法人順正学園, 宮崎, Domestic conference

    Public discourse

  • iPS細胞:次の10年に向けた出帆のために

    Aoi Takashi

    R&D協議会, May 2015, Japanese, iPSポータル株式会社, 京都, Domestic conference

    Public discourse

  • iPS細胞を用いた研究の現状

    Aoi Takashi

    明石市医師会内科医会学術講演会, May 2015, Japanese, 第一三共株式会社, 明石, Domestic conference

    Oral presentation

  • iPS細胞の消化器病学への応用

    Aoi Takashi

    第16回京都桂消化器病フォーラム, May 2015, Japanese, エーザイ株式会社, 京都, Domestic conference

    Public discourse

  • 再生医療と臨床検査

    Aoi Takashi

    第10回日本臨床検査医学会特別例会, Apr. 2015, Japanese, 日本臨床検査医学会, 京都, Domestic conference

    Oral presentation

  • iPS細胞研究の現状と臨床応用

    Aoi Takashi

    堺市医師会内科医会・外科医会合同学術講演会, Mar. 2015, Japanese, 堺市医師会, 大阪, Domestic conference

    Public discourse

  • iPS細胞の医学研究への応用

    Aoi Takashi

    第7回Cardiovascular Reseach Frontier, Feb. 2015, Japanese, バイエル薬品(株), 大阪, Domestic conference

    Public discourse

  • iPS細胞を用いる再生医療の展望

    Aoi Takashi

    兵庫県透析医会・学術講演会, Dec. 2014, Japanese, 中外製薬株式会社, 神戸, Domestic conference

    Public discourse

  • 再生医療に向けたiPS細胞研究の諸問題

    Aoi Takashi

    神戸再生医療勉強会, Oct. 2014, Japanese, 公益財団法人 先端医療振興財団, 神戸, Domestic conference

    Public discourse

  • iPS細胞の実用化研究の最前線

    Aoi Takashi

    第110回木曜会, Oct. 2014, Japanese, 神戸大学東京六甲クラブ, 東京, Domestic conference

    Public discourse

  • 臨床応用に向けたiPS細胞研究の展望

    Aoi Takashi

    第20回神戸臨床検査フォーラム, Sep. 2014, Japanese, 神戸大学医学部附属病院検査部, 神戸, Domestic conference

    Public discourse

  • iPS細胞研究の展望

    Aoi Takashi

    第50回日本医学放射線学会秋季臨床大会, Sep. 2014, Japanese, 日本医学放射線学会, 神戸, Domestic conference

    [Invited]

    Invited oral presentation

  • iPS細胞研究の基礎(iPS細胞研究の歴史と現状の紹介)

    Aoi Takashi

    第30回西宮市ライフサイエンスセミナー, Sep. 2014, Japanese, 西宮市ライフサイエンスセミナー運営委員会, 西宮, Domestic conference

    Public discourse

  • iPS細胞応用医学の消化器領域への展開

    Aoi Takashi

    第17回no Side GI Conference in 堂島, Sep. 2014, Japanese, エーザイ株式会社, 大阪, Domestic conference

    Public discourse

  • iPS細胞の臨床応用について

    Aoi Takashi

    金沢大学恒常性制御学講座 講演会, Sep. 2014, Japanese, 金沢大学大学院医学系研究科, 金沢, Domestic conference

    Public discourse

  • 新規抗パーキンソン病薬の探索

    上中 健, Satake Wataru, CHA Pei-Chieng, 岡田 随象, Aoi Takashi, Toda Tatsushi

    パーキンソン病患者由来iPS細胞を中心とする多面的疾患モデルに立脚した革新的医薬品の開発 班会議, Aug. 2014, Japanese, 日本, 東京, Domestic conference

    Oral presentation

  • iPS細胞研究の進展-黎明期から現在まで-

    Aoi Takashi

    第20回日本看護診断学会学術大会, Jul. 2014, Japanese, 関西看護医療大学, 神戸, Domestic conference

    [Invited]

    Invited oral presentation

  • iPS細胞を用いる細胞移植医療の現状と展望

    Aoi Takashi

    第4回細胞再生医療研究会, Jul. 2014, Japanese, 細胞再生医療研究会, 神戸, Domestic conference

    [Invited]

    Invited oral presentation

  • iPS細胞を用いたこれからの癌治療

    Aoi Takashi

    第41回尿路悪性腫瘍研究会, Jul. 2014, Japanese, 日本化薬株式会社, 東京, Domestic conference

    Public discourse

  • iPS細胞の臨床応用

    Aoi Takashi

    富山大学大学院セミナー, Jul. 2014, Japanese, 富山大学, 富山, Domestic conference

    Public discourse

  • iPS細胞研究の腫瘍学への展開

    Aoi Takashi

    第10回日本肝がん分子標的治療研究会, Jun. 2014, Japanese, 大阪赤十字病院 消化器内科, 兵庫, Domestic conference

    Public discourse

  • iPS細胞の医療への応用

    Aoi Takashi

    学術デー, Jun. 2014, Japanese, 尼崎市医師会, 尼崎, Domestic conference

    Public discourse

  • iPS細胞と再生医療研究のいま

    Aoi Takashi

    第7回DMFKOBE, Jun. 2014, Japanese, 日本イーライリリー株式会社, 三宮, Domestic conference

    Public discourse

  • iPS細胞がん診療への貢献の可能性

    Aoi Takashi

    がん診療連携拠点病院医療者研修会, Jun. 2014, Japanese, 兵庫県立尼崎病院, 尼崎, Domestic conference

    Public discourse

  • iPS細胞研究の展望

    Aoi Takashi

    薬学セミナー2014, May 2014, Japanese, アステラス製薬株式会社, 札幌, Domestic conference

    [Invited]

    Invited oral presentation

  • iPS細胞の基礎と臨床応用

    Aoi Takashi

    Seminar in Oncology, May 2014, Japanese, 岩手医科大学医学部, 盛岡, Domestic conference

    [Invited]

    Invited oral presentation

  • Medical Applications  of induced Pluripotent Stem, iPS cells

    Aoi Takashi

    第34回国際眼科学会, Apr. 2014, English, 日本眼科学会, 東京, Domestic conference

    [Invited]

    Invited oral presentation

  • iPS細胞の基礎と臨床応用

    Aoi Takashi

    第100回消化器病学会総会, Apr. 2014, Japanese, 消化器病学会, 東京, Domestic conference

    [Invited]

    Nominated symposium

  • Medical Applications of iPS Cells

    Aoi Takashi

    第2回ワシントン大学・神戸大学国際合同シンポジウム, Mar. 2014, English, 神戸大学大学院医学研究科, Washington, D.C., USA, International conference

    [Invited]

    Invited oral presentation

  • iPS細胞研究の現状と展望:腫瘍学への応用の可能性

    Aoi Takashi

    第86回日本胃癌学会総会, Mar. 2014, Japanese, 日本胃癌学会, 神奈川, Domestic conference

    [Invited]

    Invited oral presentation

  • iPS細胞の品質管理

    Aoi Takashi

    第13回日本再生医療学会総会, Mar. 2014, Japanese, 日本再生医療学会, 京都, Domestic conference

    [Invited]

    Invited oral presentation

  • Basic and Clinical Applications of induced Pluriportent Stem. iPS Cells

    Aoi Takashi

    Molecular Biology and lmmunology Course (Visit to UGM), Mar. 2014, English, Indonesia, International conference

    [Invited]

    Invited oral presentation

  • Basic and Clinical Application of Stem Cell

    Aoi Takashi

    Continuing Medical Education (Visit to UGM), Mar. 2014, English, Indonesia, International conference

    [Invited]

    Invited oral presentation

  • iPS細胞研究と再生医療推進の動向

    Aoi Takashi

    第8回神戸DM臨床カンファレンス, Feb. 2014, Japanese, 日本イーライリリー株式会社, 神戸, Domestic conference

    [Invited]

    Invited oral presentation

  • iPS細胞に関するアカデミアニーズについて

    Aoi Takashi

    iPS細胞ビジネス協議会 第7回情報交換会, Feb. 2014, Japanese, iPSアカデミアジャパン, 京都, Domestic conference

    Public discourse

  • iPS細胞がつくる医学のこれから

    Aoi Takashi

    東神戸 総合内科講演会, Feb. 2014, Japanese, アステラス製薬株式会社, 神戸, Domestic conference

    [Invited]

    Invited oral presentation

  • iPS細胞加工製品の実用化に向けた動向

    Aoi Takashi

    日本薬学会近畿支部 市民公開講座, Jan. 2014, Japanese, 日本薬学会近畿支部, 大阪, Domestic conference

    Public discourse

  • iPS細胞の応用、研究から実践へ

    Aoi Takashi

    第10回鬼怒川フォーラム, Jan. 2014, Japanese, 獨協医科大学病理学, 東京, Domestic conference

    [Invited]

    Invited oral presentation

  • iPS細胞研究の進展

    Aoi Takashi

    第61回日本ウイルス学会学術集会, Nov. 2013, Japanese, 日本ウイルス学会, 神戸, Domestic conference

    [Invited]

    Invited oral presentation

  • iPS細胞研究とその応用

    Aoi Takashi

    第13回神戸消化器クラスター研究会, Nov. 2013, Japanese, エーザイ株式会社, 神戸, Domestic conference

    [Invited]

    Invited oral presentation

  • 再生医学概論とiPS細胞の展望

    Aoi Takashi

    第31回神戸大学大学院医学研究科公開講座, Oct. 2013, Japanese, 神戸大学大学院医学研究科, 神戸, Domestic conference

    Public discourse

  • iPS細胞研究の進展

    Aoi Takashi

    東近江医師会学術講演会, Oct. 2013, Japanese, 東近江医師会, 滋賀, Domestic conference

    Public discourse

  • iPS細胞を用いる医学のこれから

    Aoi Takashi

    第62回近畿膵疾患懇談会, Oct. 2013, Japanese, エーザイ株式会社, 大阪, Domestic conference

    [Invited]

    Invited oral presentation

  • iPS細胞のお話とアカデミアニーズについて

    Aoi Takashi

    iPSビジネス参入促進オープンセミナー, Oct. 2013, Japanese, 中小企業基盤整備機構 近畿本部, 京都, Domestic conference

    Public discourse

  • iPS細胞と再生医療の未来

    Aoi Takashi

    大倉山祭 シンポジウム, Oct. 2013, Japanese, 神戸大学医学部, 神戸, Domestic conference

    Public discourse

  • iPS細胞と医療のこれから

    Aoi Takashi

    神戸大学ホームカミングデイ, Oct. 2013, Japanese, 神戸大学, 神戸, Domestic conference

    Public discourse

  • Gene therapy and cell therapy through the liver,current aspects and future propects

    Aoi Takashi

    JDDW2013 第17回日本肝臓学会大会, Oct. 2013, English, 日本肝臓学会, 東京, Domestic conference

    [Invited]

    Invited oral presentation

  • 臨床応用に向けたiPS細胞の今

    Aoi Takashi

    Merck Millipore BioScience Forum2013, Sep. 2013, Japanese, メルク株式会社, 東京, Domestic conference

    [Invited]

    Invited oral presentation

  • Perspectives in iPS cell Applications

    Aoi Takashi

    第4回国際MASSIN会議, Sep. 2013, English, 神戸大学医学部脳神経外科, 神戸, International conference

    [Invited]

    Invited oral presentation

  • iPS細胞研究の展開

    Aoi Takashi

    日本小児麻酔学会第19回大会, Sep. 2013, Japanese, 日本小児麻酔学会, 神戸, Domestic conference

    [Invited]

    Invited oral presentation

  • iPS細胞研究の進展

    Aoi Takashi

    第32回日本運動器移植・再生医学研究会, Sep. 2013, Japanese, 神戸大学大学院医学研究科整形外科学, 神戸, Domestic conference

    [Invited]

    Invited oral presentation

  • iPS細胞の展開~真の実用化に向けて~

    Aoi Takashi

    第33回鎮痛薬・オピオイドペプチドシンポジウム, Sep. 2013, Japanese, 神戸大学大学院医学研究科精神医学分野, 神戸, Domestic conference

    [Invited]

    Invited oral presentation

  • iPS細胞研究の現状

    Aoi Takashi

    第20回臨床細胞遺伝学セミナー, Aug. 2013, Japanese, 日本人類遺伝学会, 東京, Domestic conference

    Public discourse

  • iPS細胞を用いる癌研究の可能性

    Aoi Takashi

    がんプロ研究者養成セミナー2013, Jul. 2013, Japanese, 神戸大学大学院医学研究科, 神戸, Domestic conference

    Public discourse

  • iPS細胞の可能性を、未来へ。

    Aoi Takashi

    職員研修特別講演会, Jul. 2013, Japanese, 松江赤十字病院, 島根, Domestic conference

    Public discourse

  • iPS細胞が拓く新しい医療

    Aoi Takashi

    医学フォーラムinくにびき, Jul. 2013, Japanese, 田辺三菱製薬株式会社, 島根, Domestic conference

    Public discourse

  • iPS cell applications in medical science

    Aoi Takashi

    神戸薬科大学 特別研究セミナー, Jul. 2013, English, 神戸薬科大学, 神戸, Domestic conference

    Public discourse

  • iPS細胞研究の進展

    Aoi Takashi

    第36回消化器内視鏡若手の会, Jun. 2013, Japanese, 大日本住友製薬株式会社, 東京, Domestic conference

    [Invited]

    Invited oral presentation

  • iPS細胞研究の進展

    Aoi Takashi

    神緑会姫路支部 学術講演会, Jun. 2013, Japanese, 神緑会姫路支部, 神戸, Domestic conference

    [Invited]

    Invited oral presentation

  • iPS細胞研究の現状と臨床応用~神戸大学でのスタートを期して~

    Aoi Takashi

    神緑会 学術講演会, Jun. 2013, Japanese, 神緑会, 神戸, Domestic conference

    [Invited]

    Invited oral presentation

  • iPS細胞の使い方:初歩から応用まで

    Aoi Takashi

    第66回日本酸化ストレス学会学術集会, Jun. 2013, Japanese, 日本酸化ストレス学会, 愛知, Domestic conference

    [Invited]

    Invited oral presentation

  • iPS細胞の現状と課題

    Aoi Takashi

    日本消化器病学会四国支部第99回例会, Jun. 2013, Japanese, 日本消化器病学会, 高知, Domestic conference

    [Invited]

    Invited oral presentation

  • ここまできたiPS細胞研究:全ての患者さんに実行できる再生医療への応用の鍵を握る臨床検査

    Aoi Takashi

    第62回日本医学検査学会, May 2013, Japanese, 日本臨床衛生検査技師会, 香川, Domestic conference

    [Invited]

    Invited oral presentation

  • iPS細胞研究の展開

    Aoi Takashi

    第28回ヘルペスウイルス研究会, May 2013, Japanese, 第28回ヘルペスウイルス研究会, 神戸, Domestic conference

    [Invited]

    Invited oral presentation

  • 細胞の運命を操る技術の医学応用に向けて

    青井 貴之

    シスメックス再生医療セミナー, 02 Sep. 2021, Japanese

    Public discourse

Research Projects

  • 青井 貴之

    科学研究費補助金/基盤研究(B), Apr. 2018 - Mar. 2022, Principal investigator

    Competitive research funding

  • 河本 旭哉, 原 仁美, 深瀬 直政, 秋末 敏宏, 青井 貴之, 川上 洋平

    日本学術振興会, 科学研究費助成事業 基盤研究(C), 基盤研究(C), 神戸大学, 01 Apr. 2018 - 31 Mar. 2021

    本研究の目的は,骨肉腫の基礎研究において広く用いられている骨肉腫細胞株を用いて,iPS細胞作製技術による人工骨肉腫幹細胞の作製を行い,同細胞の幹細胞特性,腫瘍増生,治療抵抗性について,下記のごとく,形態学的,組織学的,分子生物学的に評価することにある. これまでにヒト骨肉腫由来細胞株MG63にレトロウイルスベクターを用いて,OCT3/4,KLF4,SOX2の3つの因子を導入したMG63(MG-OKS)とコントロールとしてGFPのみを導入した(MG-GFP)を作製し検討を行ったところ,MG-OKS細胞ではMG-GFPと比較して,幹細胞関連マーカーの上昇,細胞増殖能の低下,細胞遊走能の上昇,スフェア形成能の上昇など,幹細胞としての特性を示した.また,薬剤耐性能の評価としてドキソルビシンを用いた検討ではMG-OKS細胞で高抵抗性を有し,さらに骨肉腫の特徴である骨形成能をAlizarin Red S染色およびALP染色で評価したところ,MG-OKS細胞では高い染色性を示し,骨形成能の増強をみとめた.ヌードマウス背部皮下移植モデルを用いたin vivoでの検討では,MG-OKS細胞は生着率が高く,形成された腫瘍の増大も有意に強いことが明らかとなった. 以上より,ヒト骨肉腫細胞株MG63にiPS細胞作製技術と同様にOCT3/4,KLF4,SOX2の3つの因子を導入することで幹細胞としての特性を獲得するとともに,骨肉腫本来の悪性度および骨形成能の増強が得られ,人工骨肉腫幹細胞の作製が可能となった.

    Competitive research funding

  • 眞庭 謙昌

    科学研究費補助金/基盤研究(B), Apr. 2017 - Mar. 2020

    Competitive research funding

  • 掛地 吉弘

    科学研究費補助金/基盤研究(B), Apr. 2016 - Mar. 2020

    Competitive research funding

  • 曽良 一郎

    科学研究費補助金/基盤研究(B), Apr. 2016 - Mar. 2019

    Competitive research funding

  • 眞庭 謙昌

    科学研究費補助金/基盤研究(B), Apr. 2014 - Mar. 2017

    Competitive research funding

  • 青井 貴之

    学術研究助成基金助成金/基盤研究(C), Apr. 2014 - Mar. 2017, Principal investigator

    Competitive research funding

  • (AMED)福山型筋ジストロフィー及び類縁疾患の中枢細胞移動障害の回復を目指した基盤技術開発研究

    池田 真理子

    国立研究開発法人日本医療研究開発機構, 難治性疾患実用化研究事業, 2017

    Competitive research funding

  • 青井 貴之

    国立研究開発法人日本医療研究開発機構, 再生医療実現拠点ネットワークプログラム幹細胞・再生医学イノベーション創出プログラム, 2017, Principal investigator

    Competitive research funding

  • アセンブラーとしての癌/非癌幹細胞の機能解明とその制御技術の開発

    青井 貴之

    国立研究開発法人日本医療研究開発機構, 再生医療実現拠点ネットワークプログラム(幹細胞・再生医学イノベーション創出プログラム), 2016, Principal investigator

    Competitive research funding

  • Establishment of lung cancer organoids and their practical application in clinical practice

    眞庭 謙昌, 青井 貴之, 法華 大助

    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Fund for the Promotion of Joint International Research (Fostering Joint International Research (B)), Fund for the Promotion of Joint International Research (Fostering Joint International Research (B)), Kobe University, 27 Oct. 2020 - 31 Mar. 2023

  • Elucidation of the mechanism of maturation of tertiary lymph structure in gastric cancer tumor immune microenvironment and identification of the therapeutic antibodies

    掛地 吉弘, 山下 公大, 向山 順子, 中野 秀雄, 岡田 誠治, 青井 貴之, 藤田 貢, 高村 史記

    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B), Grant-in-Aid for Scientific Research (B), Kobe University, 01 Apr. 2020 - 31 Mar. 2023

  • ヒトiPS細胞由来テストステロン産生Leydig細胞の作製と臨床応用に関する実験

    藤澤 正人, 重村 克巳, 青井 貴之, 石田 貴樹, 千葉 公嗣

    日本学術振興会, 科学研究費助成事業 基盤研究(C), 基盤研究(C), 神戸大学, 01 Apr. 2020 - 31 Mar. 2023

  • Bioethics in AI - Overall Perspective and Direction for Future Researches in This Field

    位田 隆一, 青井 貴之, 清水 昌平, 森崎 隆幸, 須齋 正幸, 磯 博康, 神崎 宣次, 平澤 俊明, 児玉 聡

    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Challenging Research (Exploratory), Grant-in-Aid for Challenging Research (Exploratory), Shiga University, 30 Jul. 2020 - 31 Mar. 2022

  • ACTH産生下垂体腺腫の浸潤性、増殖性と関連するCRNDEの機能の解明

    福岡 秀規, 高橋 裕, 山田 正三, 青井 貴之

    日本学術振興会, 科学研究費助成事業 基盤研究(C), 基盤研究(C), 神戸大学, 01 Apr. 2019 - 31 Mar. 2022

    クッシング病は下垂体腫瘍の中でも診断、治療がむつかしい疾患であり、その薬物治療開発を進めることが急務である。クッシング病の原因であるACTH産生下垂体腺腫(ACTHoma)は最近の研究によりその半数がUSP8遺伝子の異常が原因となっていることが示されているが、その特徴としてホルモン分泌能は高い一方、比較的小さな腫瘍である事が知られている。一方ACTHomaの20%は1cmを超えるマクロ腺腫で、増殖浸潤能が高く、手術による緩解率が不良であるため、臨床経過に難渋することが多い。しかし、ACTHomaがどのように増殖性、浸潤能を獲得するかは明らかでない。本研究は、ACTHomaの浸潤増殖性を規定する因子を明らかにし、今後の治療標的としての可能性を探ることを目的としている。以前我々はACTHomaにおいて浸潤性を持つ腫瘍と持たない腫瘍におけるRNA発現をマイクロアレイを用いて検討したところ、その浸潤性、増殖性と関連する因子として長鎖ノンコーディングRNA(LncRNA)であるCRNDEを同定した。CRNDEは大腸癌、神経膠腫、肺癌、乳癌、腎細胞癌などにおいて増殖浸潤性に関連する因子であることが近年明らかにされ、現在ACTHomaにおいてCRNDEがどのように増殖、浸潤性を規定してるのか、その発現抑制が治療標的となりうるのかを検討している。また、CRNDEは種、臓器特異性が高いことが想定されるため、ヒト由来ACTHoma研究のモデルとしてACTHoma術後検体を用いたオルガノイドの作成を同時に行っている。

  • ヒトiPS細胞由来ライディッヒ細胞の作製

    青井貴之

    国立研究開発法人日本医療研究開発機構, 再生医療実現拠点ネットワークプログラム(技術開発個別課題), 神戸大学, Apr. 2019 - Mar. 2022

  • 細胞分化におけるCOのシグナル分子としての役割解明

    北岸 宏亮, 青井 貴之

    日本学術振興会, 科学研究費助成事業 挑戦的研究(萌芽), 挑戦的研究(萌芽), 同志社大学, 28 Jun. 2019 - 31 Mar. 2021

    細胞内一酸化炭素の効果を見るために,細胞内COを選択的に除去するツール,細胞内COを定量するツール,細胞内にCOを効率よく届けるツールをそれぞれ開発した。細胞内COを定量するツールについては,その定量アッセイを最適化することにより,広く汎用できる技術へと展開し,特許出願を果たした。また細胞内COを定量する方法を動物組織に応用し,COを吸引した動物体内におけるCOの分布について調査を進め,論文投稿準備中である。さらに細胞内COと細胞分化における関係を調べるために,分担者である神戸大・青井教授と複数回ディスカッションを行い,iPS細胞にCOを届けるツールを添加した際の細胞分化に与える影響について,現在検討を行っている。

  • Development of personalized medcicine for inflammatory bowel disease based on control of epigenome

    仲瀬 裕志, 青井 貴之, 鈴木 拓

    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B), Grant-in-Aid for Scientific Research (B), Sapporo Medical University, 01 Apr. 2018 - 31 Mar. 2021

    炎症性腸疾患(IBD)は再燃・寛解を繰りかえす原因不明の難治性疾患であるが、その発症原因は現在のところ明らかとなっていない。日本における患者数は増加の一途をたどっていることから、根治的治療の開発が望まれている。従って、その原因解明は重要な臨床課題である。欧米では IBD患者の疾患感受性遺伝子として自然免疫に関する遺伝子異常が報告された。しかしながら、欧米で見出された IBD関連遺伝子の多くは日本では認められていない。従って、 遺伝的要因のみならず、後天的な免疫担当細胞における機能異常が IBD発症に関与している可能性が示唆される。現在までの多くの研究は、IBD病態解明において、免疫担当細胞の機能異常に焦点があてられてきた。 一方で、その研究の多くは根本的なIBD病態の解明につながるものではなく、 IBD発症後の結果を解析しているものにすぎない。癌、心疾患、ア レルギー疾患などの多因子疾患は、エピゲノム変化が重要な役割を果たしていると考えられている。このような観点から、IBD発症においてもエピゲノム変化が大きく関して いる可能性が高いと推測される。このことを明らかにするためには、同一患者における自然免疫担当細のエピゲノム変化を正確に捉える必要がある。しかしながら、IBD発症前に これらの細胞の遺伝子解析を行うことは現実的には不可能である。そこで本研究においては、以下の検討を進めていく。 (1)日本人IBD患者から iPS 細胞を樹立する。(2)iPS 細胞から自然免疫担当細胞を分化誘導させる。(3)IBD発症後の患者から採取された自然免疫担当細胞とiPS細胞から分化誘導された細胞との間のエピゲノム変化を網羅的に比較検討することである。その結果に基づき、個々のIBD患者のエピゲノム変化を捉えた IBD 先制医療を目指す。

  • Homeostasis of alpha dystroglycan glycosylation in Fukuyama congenital muscular dystrophy

    池田 真理子, 青井 貴之, 青井 三千代, 丸山 達生, 石垣 景子, 中嶋 和紀, 長坂 美和子

    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B), Grant-in-Aid for Scientific Research (B), Fujita Health University, Apr. 2021 - Mar. 2026, Coinvestigator

  • Development of new treatment strategies for osteosarcoma using induced osteosarcoma stem cells

    河本 旭哉, 青井 貴之, 竹森 俊幸, 森下 雅之, 原 仁美, 秋末 敏宏

    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Kobe University, Apr. 2021 - Mar. 2024, Coinvestigator

  • Establishment of phenotype based precision medicine for mediastinal primary sarcoma using iPS technology

    田中 雄悟, 青井 貴之, 眞庭 謙昌

    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Kobe University, Apr. 2021 - Mar. 2024, Coinvestigator

  • Elucidation of the principle of cellular reprogramming in multicellular organisms

    玉田 洋介, 青井 貴之, 石川 雅樹

    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B), Grant-in-Aid for Scientific Research (B), Utsunomiya University, Apr. 2021 - Mar. 2024, Coinvestigator

  • 低分子化合物の分子凝集による酵素の新規阻害様式

    丸山 達生

    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Challenging Research (Exploratory), Grant-in-Aid for Challenging Research (Exploratory), Kobe University, Jul. 2021 - Mar. 2023

Social Contribution

  • これからの医療への貢献のかたち

    兵庫県立長田高等学校

    Lecturer, 10 Feb. 2021

  • 私たちの貢献のチャンスはどこにあるか?

    兵庫県立小野高等学校

    Lecturer, 18 Dec. 2020

  • 新しい技術を活用する医療の展開

    兵庫県立長田高等学校

    Lecturer, 12 Feb. 2020

  • 「なるほど医学体験!HANSHIN健康メッセ」実行委員

    Advisor

  • 日本再生医療学会「リスクコミュニケーションのモデル形成事業」市民講座

    Lecturer

  • 兵庫県立長田高校 出前講義

    Lecturer

  • 兵庫県立小野高校 研究室見学・研究サポーター

    Advisor